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The genomic dimension of legislations across EU 
This report presents a mapping, as complete as possible, of existing national legislations linked to genomics. It 
can be used as a baseline for the analyses of possible consequences for EU policies already in place, and to 
forecast policy gaps and eventual interventions. 
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Executive summary 
With the advent of fast, high efficiency and low cost DNA sequencing techniques, the 
ability to study the human genome by reading the sequence of its DNA is growing 
exponentially, with a resulting tremendous impact on many fields of scientific research. 
The application of genomics inside routine healthcare is boosting preventive medicine 
practices and can lead to personalised treatments that can highly improve the healthcare 
services and patients' health, and in the same time provide a wealth of data for medical 
research. 
In parallel, this has also led to the spread of commercial opportunities to provide 
consumers with the possibility of sequencing their genomes in a way which is both 
appealing and affordable. These commercial offers, however, do not always ensure the 
security of the generated data. In addition, the accuracy and reliability of the offered 
findings are not homogenous, as there are no standards to guarantee that the quality of 
the outputs satisfies minimum requirements - in fact, no agreements yet exist on the 
definition of these requirements. 
In this frame, a comprehensive knowledge of what is present at the legislative level in 
the member states of the European Union (plus Switzerland, Iceland and Norway) 
regarding the regulatory oversight of genomics technologies is of fundamental 
importance to frame the status of existing European norms, to understand whether 
possible incompatibilities might arise between frameworks and to highlight eventual 
gaps. 
 
Policy context 
Various EU countries have ongoing or planned initiatives to sequence the genomes of 
large numbers of their citizens, as they launched, funded or are going to approve 
national personalised medicine programmes or initiatives based on genomics, to improve 
the diagnosis and prevention of human diseases, from (rare) monogenic syndromes to 
cancer.  With the 'Declaration of Cooperation Towards access to at least 1 million 
sequenced genomes in the European Union by 2022', that was signed by 13 European 
countries, there is a strong commitment to share and combine this accumulated 
knowledge of genomic information. It is thus crucial, for this endeavour, to identify where 
there might be potential legislative obstacles in linking human genomics resources across 
countries, and to propose effective and efficient means to overcome them. 
This report also feeds, more generally, into the ongoing activities within the JRC on 
eHealth and Big Data, both related to the implementation of the EC Digital Single Market 
strategy. Genomics will have a profound impact on personalised medicine, improving the 
screening, diagnosis and prevention of diseases, and may become an important 
component of a harmonised electronic health record for each EU citizen. 
 
Key conclusions 
This report highlights that: 
1. The existing national legislations seem to focus on genes, their variations and 
hereditability in living organisms, while scientific interests and advancements, at the 
moment, have a more holistic view of the genomes of living organisms. Further 
reflections are needed to address this important gap in the legislative framework. 
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2. There is a number of areas that are differentially addressed in the regulatory 
frameworks of the different member states, such as human somatic and germ line 
modifications (through the application of gene and genome editing technologies),  
3. Different legislative frameworks take into consideration the citizens'/patients' rights of 
having their personal genomic data characterised, used and shared. 
An online interactive compendium should be produced and released, that would include 
all the legislative instruments retrieved and analysed for this report. 
 
Main findings 
This report presents a mapping, as complete as possible, of all existing (in force, and 
coming into force) national legislations regarding topics linked to genomics. The analysis 
of the content of the retrieved legislations highlighted as main common regulated areas 
provisions on GMOs, genetics in general, embryo research, criminal legislation, patents, 
data protection, discrimination, and genetics applied to employment, insurances and 
inheritance processes.  
The mapping of the available legislation at the national level, summarised and analysed 
in this report, can be used as a baseline for the analyses of possible consequences for EU 
policies already in place, and to forecast policy gaps and eventual interventions. 
 
Related and future JRC work 
The first immediate next step will be the implementation of an online interactive 
compendium of all the retrieved legislative instruments, intended for public use.  
Moreover the content of the report, as a deliverable the Omics in Society transversal 
action, can be of high interest for JRC Units dealing with ethics, cybersecurity, data 
privacy & protection, environment, law in general, and for other DGs of the European 
Commission (e.g.: RTD, SANTE, CONNECT, HOME, GROW, ENV). 
 
Quick guide 
The aim of this report is to provide an overview, as complete as possible, of the current 
legislations within the European Union member states, as well as Switzerland, Iceland 
and Norway, applying to Genomics. 
The search for the legislative material has been performed through dedicated websites 
(both governmental and private) in each country that collect the national legislations. 
Whenever possible, the search functions of the websites have been used to retrieve the 
documentation. When this was not possible, other means to identify the correct 
documents had to be applied, on a case-by-case basis. Whenever possible, the English 
version of the documents (both official and non-official) has been preferred. Where no 
English translation was available, legislations were retrieved in their original language 
and then translated (using, if needed, the European Commission translation services). 
Based on the material retrieved, a comprehensive analysis of the content was performed, 
highlighting communalities, as well as gaps, discrepancies and potential controversies. 
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1 Introduction 
 
The aim of this report is to provide an overview, as complete as possible, of the current 
legislations within the European Union member states, as well as Switzerland, Iceland 
and Norway, applying to genomics, highlighting communalities as well as gaps, 
discrepancies and potential controversies. The report first highlights general trends in the 
types of legislation in place and the topics they cover. The second part of the report 
summarises key findings from each of the 31 jurisdictions covered. These summaries 
outline the scope of local law and highlight obvious omissions or outliers. A description of 
the methods employed in producing the accompanying individual country reports is also 
included. 
According to the WHO definitions, "Genetics is the study of heredity", while "Genomics is 
defined as the study of genes and their functions, and related techniques". According to 
this definition, "the main difference between genomics and genetics is that genetics 
scrutinizes the functioning and composition of the single gene whereas genomics 
addresses all genes and their inter relationships in order to identify their combined 
influence on the growth and development of the organism" (1). According to the 
European Bioinformatics Institute (EMBL-EBI) "Genomics is the study of whole genomes 
of organisms, and incorporates elements from genetics and it differs from 'classical 
genetics' in that it considers an organism’s full complement of hereditary material, rather 
than one gene or one gene product at a time." (2).  
Genomics come with two main topics that need to be addressed from a legal point of 
view: the production/handling of genomic information, and the use of new genomic 
technologies that are developed and use this information. For example, the application of 
genomic sequencing technology in a number of contexts continues to grow, ranging from 
the detection of crime to the identification of the causes of disease. Linked to the latter, 
there has been an increasing interest around the use of CRISPR-Cas9 DNA editing 
technologies, which can be used to edit the genome of any living organism, enabling 
precise cutting and pasting of DNA by specialized proteins. The potential uses of genomic 
information and technologies raises a number of significant social and ethical dilemmas, 
particularly on when, and how, these uses should be regulated. 
  
 
                                           
(1) WHO definitions of genetics and genomics: http://www.who.int/genomics/geneticsVSgenomics/en/ 
 
(2) What is genomics? https://www.ebi.ac.uk/training/online/course/genomics-introduction-ebi-
resources/what-genomics 
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2 General trends  
2.1 Outlier Jurisdictions 
 
The depth of regulation relevant to genetics varies starkly across the 31 analysed 
jurisdictions. Some have only a few tangentially related laws relating to genetics whilst 
others have a more comprehensive regulatory framework. According to our findings, the 
most comprehensive coverage of issues relating to genetics, and embryonic research is 
probably to be found in Switzerland. Swiss legislation provides a good example of a truly 
wide-ranging engagement with genetics, encompassing the Swiss Federal Act on 
Research Involving Embryonic Stem Cells (2003) and Federal Act on Human Genetic 
Testing (2004) and the Federal Act on Research Involving Human Beings (2011).   
 
The other jurisdictions which have a comprehensive coverage of issues are: Norway, 
Lithuania, Latvia, Portugal, Estonia and Hungary. These jurisdictions have enacted 
bespoke genetic research laws, which engage deeply with the issues of genetic research, 
embryo research and genetic testing. The laws specify the time limitations on how long 
an embryo can be used in research and provide for prohibitions on germ-line alterations. 
 
Jurisdictions which have only few legislative instruments relating to genetics, and the 
instruments enacted focus mainly on the environment and Genetically Modified 
Organisms (‘GMO’), are: Bulgaria, Czech Republic, Slovakia, Greece, Ireland and Poland. 
 
 
2.2 Genetically Modified Organisms 
The most heavily legislated area in relation to genetics in the European Union (and 
Norway, Iceland and Switzerland) appears to be the use of GMOs in agriculture, foods 
and consumer products. Almost all 31 jurisdictions have passed comprehensive 
legislation which covers the licensing for GMOs, their handling and safety requirements. 
The legislative instruments identified throughout the course of this review, appear 
substantially the same and derive from the following European instruments: Directive 
2001/18/EC on the deliberate release of GMOs into the environment; Regulation (EC) 
1829/2003 on genetically modified food and feed; Directive (EU) 2015/412 amending 
Directive 2001/18/EC as regards the possibility for the Member States to restrict or 
prohibit the cultivation of GMOs in their territory; Regulation (EC) 1830/2003 concerning 
the traceability and labelling of genetically modified organisms and the traceability of 
food and feed products produced from genetically modified organisms; Directive 
2009/41/EC on contained use of genetically modified micro-organisms; and Regulation 
(EC) 1946/2003 on transboundary movements of GMOs.  The Commission Directive (EU) 
2018/350 of 8 March 2018 amending Directive 2001/18/EC of the European Parliament 
and of the Council as regards the environmental risk assessment of genetically modified 
organisms was published on 9 March 2018 and comes into effect in September 2018. 
 
The legislative provisions mirror the EU legislation and are divided into provisions for the 
contained use of GMOs, deliberate release of GMOs and placing of GMOs on the market. 
Most jurisdictions appear to have essentially the same legislation with respect to GMOs 
and require almost identical safety procedures. All surveyed jurisdictions (with the 
exception of Greece, where no relevant statute could be located), require persons to 
obtain a permit to use GMOs, the application process for such permits is largely the same 
in all the relevant countries. One difference is that some jurisdictions have promulgated 
 8 
the GMO rules via primary legislation, whilst others through secondary legislation, as is 
the case for example with the UK, where most of the detail is contained in regulations; 
compared with say Cyprus where the detailed provisions on handling, licensing and use 
of GMOs are contained in primary legislative acts.  
 
See the table below for a summary of each country and the key legislative instruments 
relating to GMOs.  
 
Table 1. Summary of key legislative instruments relating to GMOs. 
COUNTRY LAW 
Austria The Gene Technology Act  
Belgium Royal Decree regulating the deliberate release into the environment and 
the placing on the market of genetically modified organisms or products 
containing GMOs (2004) 
Bulgaria The Law on Genetically Modified Organisms (2005)  
Croatia Act on Genetically Modified Organisms (2005)  
Cyprus Genetically Modified Organisms (Release into the Environment) Law of 
2003 (160(I)/2003) 
Genetically Modified Organisms (Limited and Contained Use) Law of 2004 
(15(I)/2004) 
Czech 
Republic 
Law N. 78/2004 
Denmark The Environment and Genetic Engineering Act No.9 of 4/1/2017 
Estonia The Contained Use of Genetically Modified Micro-organisms Act (2001) 
Release into Environment of Genetically Modified Organisms Act (2004) 
Finland The Gene Technology Act 17.3.1995/377 
France The Environmental Code 
Germany The Genetic Engineering Act (1993) 
Greece N/A 
Hungary The XXVII Law on Genetic Engineering (1998) 
Iceland The Act on GMOs (1996) 
Ireland The Environmental Protection Agency Act 1992 
Italy The Environmental rules – Legislative Decree of 3 April 2006, no 152 
Latvia The Law on Circulation of Genetically Modified Organisms (2007) 
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Lithuania The Law on Genetically Modified Organisms (2001) 
Luxembourg The Law of 13 January 1997 on the Control of the Use and Dissemination 
of Genetically Modified Organisms 
Malta The Contained Use of Genetically Modified Micro-Organisms Regulations 
(2008) 
the Deliberate Release into the Environment of Genetically Modified 
Organisms Regulations (2010) 
Norway The Law on the production and use of genetically modified organisms 
etc. (Genetic Technology Act) (1993) 
Poland Act of 22 June 2001 on Microorganisms and genetically modified 
organisms 
Portugal The Law no 55/2015 of 17 April on the Confined Use of Genetically 
Modified Microorganisms and Organisms 
Romania Law no. 214 of 19 April 2002 for the approval of the Government 
Ordinance no. 49/2000 
Law no. 3 of 9 January 2008 for the approval of Government Emergency 
Ordinance no. 44/2007 
Law no. 247 of 30 June 2009 for the approval of Government Emergency 
Ordinance no. 43/2007 
Slovakia The Law on Genetically Modified Organisms and Genetic Technologies 
151/2002 
Slovenia The Act on the Management of Genetically Modified Organisms (2002) 
Spain Law 9/2003 Use of Genetically Modified Organisms  
Sweden The Environmental bar (Code) 
Switzerland The Federal Act on Non-human Gene Technology (2003) 
United 
Kingdom 
The Environmental Protection Act 1990 
 
2.3 Genetics in general 
 
Many jurisdictions expressly forbid genetic modification of the human germ line, but 
some expressly allow modifications for the purposes of prevention, diagnosis or 
treatment as long as the intent is not to modify the germ line. Such provisions arguably 
open the door to utilising the potential beneficial somatic gene therapies arising out of 
applications of technologies such as CRISPR-Cas9. An example of such legislation is the 
Lithuanian Law on Ethics in Biomedical Research (2002), which provides that human 
biomedical studies which modify the human genome may only be carried out for the 
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purposes of prevention, diagnosis or treatment and only in cases where they are not 
intended to modify the progeny genome (the germ line). 
 
A number of jurisdictions address the modification of the human germ line, which is 
usually prohibited when mentioned. The majority of jurisdictions, however do not appear 
to have specific prohibition on germ line alterations in humans. It is worth noting that 
essentially all 31 surveyed countries prohibit patents for germline alteration processes, 
which in itself may have a dampening effect on the use of any such processes, even in 
the absence of a specific legislative prohibition.  
 
See below for a list of countries which address germ line alterations in some way. Note 
that many of these statutes are specifically targeted at embryo research.  
 
Table 2. Summary of key legislative instruments relating to germ line alterations. 
COUNTRY LAW NOTES 
Austria The Gene Technology Act The Act allows for the use of genetic 
analysis in medical context, to detect 
diseases which are based on germ line 
mutation, especially in cases where there is 
scope for prevention of a disease occurring 
in the future.  
Croatia The Law on the Protection of 
Patient’s Rights (2004) 
The law specifies that interventions directed 
at changing the human genome can only be 
undertaken for preventative or therapeutic 
purposes and no interventions are allowed 
with the view to changing the patient’s 
germ line. 
Germany The Embryo Protection Act 
(1990) No 69/1990 
The Act in Article 5 strictly prohibits the 
alteration of the human germ line and 
provides that any breaches of the provision 
are punishable by up to 5 years in prison. 
Lithuania The Law on Artificial 
Fertilisation (2014) 
The law prohibits the use of IVF as a means 
of modifying the identity of the germ line of 
a person or their offspring. 
 The Law on Ethics in 
Biomedical Research (2002) 
The law provides further that human 
cloning is prohibited; and biomedical 
studies which modify the human genome 
may only be carried out for the purposes of 
prevention, diagnosis or treatment and only 
in cases where they are not intended to 
modify the progeny genome (the germ 
line). 
Malta The Embryo Protection Act 
(2013) 
Section 13 specifies that it is a criminal 
offence punishable by imprisonment and a 
substantial fine to alter in an artificial way 
the genetic information of a human germ 
line; it is also an offence to knowingly use 
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such a cell. 
Netherlands The Law on Medical 
Research on Humans of 26 
February 1998 
The law forbids experimentations on 
humans in a way that changes the germ 
line of humans. 
Portugal The Law no 12/2015 of 26 
January on Personal Genetic 
Information and Health 
Information 
The Law prohibits the alteration of the 
human germ line. 
Slovenia Medicines Law (2014) The law specifies that no clinical trials can 
be conducted where the drug/treatment 
would change the germ line of the patient. 
Switzerland The Federal Act on Research 
Involving Embryonic Stem 
Cells (2003) 
The Act prohibits modification of genetic 
material in a germ cell, the derivation of 
embryonic stem cells from an embryo that 
has undergone germ line modification, or 
any use of such cells. 
United 
Kingdom 
The Human Fertilisation and 
Embryology Act 1990 
The Act regulates through licences and third 
party agreements the storage, testing, 
processing and distribution of germ cells 
that are otherwise forbidden. 
 
2.4 Embryo Research 
 
The most common limit on embryo research in the jurisdictions where specific legislation 
could be located is that it is prohibited to cultivate and use embryos for research 
purposes for more than 14 days outside of the body or until the primitive streak has 
developed. Common is also some kind of a committee or an ethics body which must give 
permission for a research project to commence. An example of such a body is the Human 
Fertilisation and Embryology Authority in the UK.  
 
Several jurisdictions have reasonably similar provisions on using embryos for research, 
such as the Icelandic Law on Artificial Fertilisation and the Use of Human Embryos and 
Embryos for Stem Cell Research (1996). This provides that embryos may be used for 
research in certain circumstances when they are not intended for in vitro fertilisation 
(IVF) and the research would yield useful scientific and medical knowledge, but all 
projects must be permitted by the Bioethics Committee. It must also be shown that there 
is no other way to conduct the research. It is prohibited to cultivate or produce embryos 
solely for research purposes and to retain embryos for more than 14 days outside the 
body, or once the primitive streak has developed. It is also prohibited to perform nuclear 
transfer for reproductive purposes (cloning) and transplant human embryos into animals. 
Similar provisions are in place in the UK, France, Sweden, Switzerland, Lithuania and 
Latvia.  
 
The statutes are often primarily targeted at regulation of IVF and place limits on genetic 
alterations of embryos used for artificial fertilisation purposes. Note that most of the 31 
jurisdictions’ patents statutes provide for prohibitions of patents for commercial uses of 
embryos. For details see the ‘patent’ section below.  
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See below for a list of countries, which have specific provisions on embryo research 
relating to genetics, and brief description of the main points from the relevant legislative 
instruments.  
 
Table 3. Summary of key legislative instruments relating to embryo research. 
COUNTRY LAW NOTES 
Belgium In vitro Research 
on Embryos Act 
of 11 May 2003 
The law permits research on embryos within the first 
14 days of fertilization. The law specifies that any such 
research must be targeted at obtaining valuable 
knowledge relevant to health. The Law prohibits 
productions of embryos specifically for research and 
provides for how can permits for embryonic research 
be obtained.  
Croatia The Act on 
Assisted 
Reproduction 
(2012) 
The Act provides for rules on donating eggs and sperm 
as well as embryos and the allowed use of these. It 
prohibits sex selection of a foetus, unless it is to 
prevent a sex-linked condition, and research on 
embryos and their alteration is generally prohibited. 
Estonia The Artificial 
Insemination and 
Embryo 
Protection Act 
(1997) 
The Act prohibits the sex selection of embryos in IVF 
procedures except where there is a high probability of 
occurrence of a genetic disease linked to the sex 
chromosome. It is also prohibited to clone embryos or 
fuse the genetic information of embryos in order to 
create a cell fusion, if one of the embryos is a human 
embryo. 
Finland The Penal Code  The Code provides that it is an offence to clone a 
human, altering and generating human germ cells and 
animal genetic material and the generation of a human 
by combining embryos. These offences are punishable 
by imprisonment of up to 2 years. 
France Law on Bioethics The Act provides that research on human embryos, 
embryonic stem cells and stem cell lines is generally 
prohibited. However, such research can be permitted if 
the scientific relevance of the research project is 
established, when the research is likely to allow major 
medical progress and the research cannot be 
performed any other way without the use of human 
embryos, embryonic stem cells or stem cell lines. Any 
such projects must be authorised by the Biomedicine 
Agency and adhere to the ethical codes promulgated 
by the Agency. The Article also specifies which 
embryos may be used for such research. 
Germany  The Embryo 
Protection Act 
(1990) 
The Act prohibits selection of embryos on the basis of 
sex except for cases where it is to prevent Duchenne 
muscular dystrophy or a similarly serious sex-linked 
genetic disease; prohibits the genetic examination of 
the cells of an embryo in vitro prior to intrauterine 
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transfer. The Act in Article 6 further provides that it is 
prohibited to clone an embryo and place any such 
embryo into the womb.  In Article 7 the Act prohibits 
creation of chimera and hybrid formation and placing 
any such creations into a womb. 
Greece The Law 3305 
Applying Medical 
Assisted 
Reproduction 
The law governs research on cells and embryos which 
are not destined for pregnancy. Research can be 
carried out to expand human knowledge and to 
improve diagnosis and treatment methods for infertility 
as well as contraception, to develop and control 
treatment techniques for genetic diseases and 
abnormalities and to study the biology of embryonic 
cells and their possible therapeutic uses. A licence is 
necessary for any such research. 
Iceland The Law on 
Artificial 
Fertilisation and 
the Use of 
Human Embryos 
and Embryos for 
Stem Cell 
Research (1996) 
Embryos may be used for research in certain 
circumstances when they are not intended for IVF and 
the research would yield useful scientific and medical 
knowledge, but all projects must be permitted by the 
Bioethics Committee. It must also be shown that there 
is no other way to conduct the research. It is 
prohibited to cultivate or produce embryos solely for 
research purposes and have embryos for more than 14 
days outside the body or once the primitive streak has 
developed. It is also prohibited to perform nuclear 
transfer for reproductive purposes (cloning) and 
transplant human embryos into animals. 
Italy The Law of 19th 
February 2004 n 
40 – Rules on 
Medically 
Assisted 
Procreation 
As per Article 13, experimentation on embryos is 
forbidden, any form of eugenic selections of embryos 
or gametes through any techniques aimed at altering 
the genetic information of the embryo or gamete or 
‘designing’ the genetic characteristics of an embryo is 
also forbidden. Exceptions are allowed for disease-
prevention. 
Lithuania The Law on 
Ethics in 
Biomedical 
Research (2002) 
The law provides that where human embryos or 
foetuses are used in biomedical studies, only those 
where the benefits are expected to outweigh the risks 
for the human embryo and human foetus are allowed. 
Malta The Embryo 
Protection Act 
(2013) 
The Act prohibits the selection of embryos based on 
the presence or absence of a sex-chromosome, except 
where it is done to prevent the occurrence of a sex-
linked genetic illness. It is an offence to unite embryos 
with different genetic material to a cell conglomerate 
using at least one human embryo. It is also an offence 
to join a human embryo with a cell that contains 
genetic information different from the embryo cells and 
induces them to develop further. 
Netherlands The Embryo Law 
of 20 June 2002  
The Law forbids all actions involving germ cells or 
embryos with a view to the birth of a genetically 
identical human being, or to deliberately modify the 
genetic material of the nucleus of human germ cells 
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which might establish a pregnancy. 
Norway The Act on 
Human Medicine 
Use of 
Biotechnology, 
etc. 
(Biotechnology 
Act) (2003) 
The law regulates when fertilised eggs may be used for 
research; prohibits research that causes genetic 
changes which may be inherited in humans; and 
prohibits production of embryos by cloning.   
Portugal The Law no 
32/2006 of 26 
July on Medically 
Assisted 
Procreation 
It is forbidden to sex-select embryos other than for the 
purpose of preventing a serious sex-linked genetic 
disease. It is forbidden to use pre-implantation genetic 
diagnosis for multifactorial diseases where the 
predictive value of the test is very low. Use of embryos 
in research is only allowed when the research is 
expected to be of great benefit to humanity. There are 
limits on what embryos are allowed to be used for 
research; one source of embryos is embryos which 
have been identified in pre-implantation genetic 
diagnosis as having a severe genetic abnormality. 
Romania Civil Code of 17 
July 2009 (Law 
287/2009) 
The Code prohibits the choosing of the sex of an 
embryo unless the reason for the choice is to avoid or 
prevent a genetic disease 
Sweden The Act on 
Biobanks in 
Healthcare, etc. 
2002:297 
The Act provides that research on embryos can be 
performed if the ethics committee approves the project 
and the embryo can be used for up to 14 days post 
fertilisation and limits the time of freezing of 
eggs/embryos to 5 years.  
Switzerland Federal 
Constitution of 
Switzerland 
It provides for the following: all forms of cloning and 
interference with the genetic material of human 
reproductive cells and embryos is unlawful; non-
human reproductive and genetic material may neither 
be introduced into nor combined with human 
reproductive material; IVF may only be used if there is 
an infertility issue or a risk of transmitting a serious 
illness and donation of embryos is unlawful. 
The Federal Act 
on Medically 
Assisted 
Reproduction 
(1998) 
The Law restricts analysis of genetic material of 
reproductive cells and embryos in vitro is to cases 
where selection of sex or other characteristics is 
necessary because of a risk that the presence of 
certain genes will inhibit the developmental capacity of 
the embryo and when there is no other way of 
avoiding a serious disease. 
 
The Act also regulates how and when reproductive 
cells can be preserved, namely with the consent of the 
donor and for a maximum of 5 years and limits the 
number of embryos developed in the IVF context per 
woman to a maximum number of twelve. The Act 
creates an offence for acts whereby a person who in 
the course of a reproductive technique analyses the 
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genetic material of reproductive cells or embryos in 
vitro and selects them according to their sex or 
according to other characteristics, without aiming to 
overcome infertility or avoid the transmission of the 
predisposition to a serious disease to the offspring 
shall be liable to a custodial sentence not exceeding 
three years or to a monetary penalty 
The Federal Act 
on Research 
Involving 
Embryonic Stem 
Cells (2003) 
The Act prohibits a number of acts including the 
creation of an embryo for research purposes, the 
modification of the genetic material in a germ cell, the 
derivation of embryonic stem cells from an embryo 
that has undergone germ line modification, or the use 
of such cells; it is also prohibited to create a clone, 
chimer or a hybrid. 
United 
Kingdom 
The Human 
Fertilisation and 
Embryology Act 
1990 
The Act prohibits a number of acts including the 
creation of an embryo, except when holding a licence 
issued by the Authority. Generally speaking, without 
authorisation, there cannot be any genetic alterations 
of eggs and sperm and no person shall use modified 
germ cells to provide fertility services. The Act also 
provides for prohibitions in connection to genetic 
material of non-human origin, namely  that (1) no 
person shall place in a woman a human admixed 
embryo, other embryo that is not a human embryo or 
gametes that are not human gametes; (2) no person 
shall mix human gametes with animal gametes, bring 
about the creation of a human admixed embryo or 
keep or use such an embryo;  (3) licences cannot 
authorise the keeping or using of a human admixed 
embryo after the appearance of the primitive streak or 
the end of 14 days beginning with the day on which 
the process of creating the embryo began and (4) 
licences cannot authorise placing human admixed 
embryos in an animal or keeping or using a human 
admixed embryo in any circumstances in which 
regulations prohibit it. Hence there is a hard limit of 14 
days for embryonic research from the time of 
fertilisation. 
2.5 Criminal Legislation 
 
Numerous jurisdictions provide for gene-related offences. The offences are related to 
cloning, modifying germ line of humans or dispersing GMOs without appropriate 
authorisations. The specific offences vary from country to country to a large degree, but 
there is a common thread of offences related to GMOs and cloning. 
 
For example, the Spanish Penal Code creates several offences relating to genetic 
information modification. Genetic modification in humans is prohibited for all purposes 
except for those where the aim is to eliminate or reduce defect or serious disease. Or, 
the Italian Law of 19th February 2004 n40 – Rules on Medically Assisted Procreation 
prohibits behaviour which may lead to cloning a person. This act is punishable by 10-20 
years in prison and a substantial monetary penalty.  
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Most jurisdictions also cover the collection, handling and storage of DNA in criminal 
investigations and/or proceedings. The idea is generally broadly the same; the law 
provides that subjects must often consent, but carves out when consent is not necessary 
and regulates the way the DNA is collected, stored and analysed as well as destroyed. An 
example is the Portuguese Law no 5/2008 of 12 February on the DNA Profile Database – 
Civil and Criminal Identification regulates and establishes DNA profile database for both 
criminal and civil litigation. 
 
A number of jurisdictions provides for specific DNA databases used in their criminal 
justice systems. These are usually designed to store DNA profiles for identification of 
suspects and convicts in criminal investigations and/or proceedings.  
 
See below for details of criminal legislation in each jurisdiction relating to genetics. The 
table provides details of all relevant legislative instruments in the criminal context and 
highlights the existence of DNA databases, where these have been found to be in place.  
 
Table 4. Summary of details of criminal legislations relating to genetics. 
COUNTRY LAW ACCESS / NOTES 
Austria Criminal Procedure 
Code  
The Act limits the use of genetic data collected 
from suspects and convicts to the purpose. 
Aliens Police Act 
100/2015 
The Act provides for public authority powers in 
some very limited circumstances to check a 
person’s DNA to confirm their identity, especially 
to prove a familial relationship in cases of family 
migration. 
Border Control Act 
435/1996 
The Act provides for public authority powers in 
some very limited circumstances to check a 
person’s DNA to confirm their identity, especially 
to prove a familial relationship in cases of family 
migration. 
Citizenship Law 
311/1985 
The Act provides for public authority powers in 
some very limited circumstances to check a 
person’s DNA to confirm their identity, especially 
to prove a familial relationship in cases of family 
migration. 
Croatia The Criminal 
Procedure Code 
The Code provides for how DNA is to be handled 
during and after criminal investigations and which 
persons have the authority to access the genetic 
data, when the data are to be destroyed and what 
consents are necessary from the subject of the 
investigation. 
Czech 
Republic  
Law N. 227/2006 
(The Penal Code) 
The Code specifies certain acts as offences; these 
include handling and using human genetic 
information in prohibited ways. These prohibited 
acts relate especially, to breaches of 
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confidentiality. 
Denmark The Law on 
processing of 
personal data by law 
enforcement 
authorities No. 410 
of 27/4/2017 
The Law regulates how police and associated 
authorities can process personal data. 
The Act on 
Establishment of a 
central DNA profile 
register No. 434 of 
31/5/2000 
The Act establishes a central DNA profile register. 
Estonia The Forensic 
Examination Act 
(2001) 
The Act establishes a National DNA Database for 
storing and collecting DNA of prisoners and 
suspects in criminal matters. 
The Imprisonment 
Act (2000) 
The Act provides for the way prisoners’ DNA 
samples are to be handled. 
Finland The Penal Code The Code specifies offences related to genetics. It 
is an offence to clone human, altering and 
generating human germ cells and animal genetic 
material and the generation of a human by 
combining embryos. These offences are punishable 
by imprisonment of up to 2 years. It is also 
prohibited to intentionally spread GMOs in violation 
of the Gene Technology Act and export GMOs 
without a licence. 
The Coercive 
Measures Act 
The Act provides for situations when DNA can be 
collected from criminal suspects and specifies how 
the samples and any resulting data are to be 
handled, stored and destroyed. 
France The Penal Code The Code outlines numerous offences related to 
genetics when a person breaches provisions 
relating to examination of a person’s genetic 
characteristics and breaches provisions of 
biomedical ethics. The Code also provides and 
establishes the national automated DNA file and 
provides how it shall be operated and who has 
access to the information thereby contained. 
Germany The Code of Criminal 
Procedure (1987) 
The Code provides for how DNA is to be used in 
the context of criminal investigations, it limits the 
scope of genetic analysis which can be performed 
on samples and specifies how DNA samples can be 
collected and when consent for collection is not 
necessary. 
Hungary The LXVI Law on the 
Registration of 
Citizen’s Personal 
Data and Address 
The Law provides for DNA procedures in criminal 
context It specifies when DNA samples can be 
taken from suspects or convicted persons, how 
and when DNA samples must be registered and 
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(1992) how DNA can be shared with other EU countries. 
The Law also provides for how long DNA is kept in 
the database and how it is to be stored. 
Iceland The Law on Genetic 
Register of Police 
(2001) 
It establishes the Icelandic DNA database for 
storing and comparing DNA of suspects and 
convicts. The Law specifies when and how DNA 
can be collected, when must it be destroyed, who 
can have access to the information; and provides 
that the Data Protection Authority shall ensure 
proper administration of the database and protect 
the privacy of the individuals whose information is 
contained in the database. 
Ireland Criminal Justice 
(Forensic Evidence 
and DNA Database 
System) 2014 Act 
The Act establishes the DNA database, as well as 
the framework for when DNA samples can be 
taken from suspects and the procedures for 
collection, storage and handling of the samples 
and any resulting data.  
Latvia The Law on 
Development and 
Use of National DNA 
Database (2004) 
The law establishes a national DNA database to 
record criminal offences; the Law also regulates 
the exchange of the results of GNA genetic 
analysis with other States and international 
organisations. 
Lithuania The Police Law 
(2000) 
The Law authorises relevant officials to take 
samples of genetic material without consent for 
comparative study and identification purposes 
 The Law on the 
Approval, Entry into 
Effect and 
Implementation of 
Criminal Procedure 
(2002) 
The Law provides when suspects’ genetic 
information can be taken, despite the lack of 
consent of the suspect. 
Luxembourg The Penal Code It provides for the use of DNA in the context of 
criminal proceedings. It specifies when DNA 
samples can be collected from suspects or convicts 
and the exact procedure of doing so. It provides 
for the protection of all DNA data collected and 
how the samples are to be stored and handled. 
Malta The Criminal Code 
(1854) 
The Code specifies who can collect DNA in criminal 
proceedings and when DNA can be transmitted 
outside Malta 
Netherlands The Code of Criminal 
Procedure of 15 
January 1921 
The Code provides for when DNA samples can be 
taken with and without consent from suspects; 
and specifies the collection procedure, handling 
and analysis of all DNA samples in the context of a 
criminal investigation and/or proceeding. 
Law on DNA and 
Convicted Persons of 
The Law provides further details on how DNA 
analysis is to be carried out in the context of a 
criminal proceeding and specifies when collections 
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16 September 2004 of DNA samples are allowed. 
Portugal  The Law no 5/2008 
of 12 February on 
the DNA Profile 
Database – Civil and 
Criminal 
Identification 
The Law regulates how the DNA data is to be 
stored and handled and what safety measures 
must be in place and for what purposes can DNA 
be collected.  
Romania Code of Criminal 
procedure of 1 July 
2010 (Law 
135/2010) 
The Law outlines when genetic samples can be 
taken in the context of criminal proceedings 
and/or investigation 
The Law no. 76 of 8 
April 2008 on the 
organisation and 
operation of the 
National System of 
Judicial Genetic Data 
The Law establishes the National System of 
Judicial Genetic Data and sets out the conditions 
under which DNA samples can be taken from 
suspects and convicts; and how the data is to be 
processed and stored. 
Slovakia Criminal Law 
300/2005 
The Law prohibits the creation of a genetically 
identical human being to another one alive or 
dead. It is also an offence to breach the laws 
relating to GMOs and genetic technologies. 
Slovenia Law on Police Orders 
and Authorisations 
(2013) 
The Law provides limits on police powers. It 
stipulates a principle of equal treatment 
prohibiting police offices to discriminate against 
anyone on the grounds of genetic heritage (Art 
14). 
Spain Penal Code The Code provides for when DNA samples can be 
taken for suspects and convicts; and outlines the 
procedures for collecting, storing and destroying 
DNA. The Code creates several offences relating to 
genetic information modification. Genetic 
modification in humans is prohibited for all 
purposes, except for those where the aim is to 
eliminate or reduce defect or serious disease. 
Breach of this provision carries a prison sentence. 
As per section 160, the use of genetic engineering 
to produce biological weapons is prohibited and 
punishable by imprisonment. It is prohibited to 
fertilise human eggs for any other purpose than 
for human reproduction; this provision carries a 
custodial sentence. The creation of genetically-
identical humans (clones) is prohibited and will be 
punished by imprisonment. 
United 
Kingdom 
The Police and 
Criminal Evidence Act 
1984 
The Act regulates when DNA profiles can be 
included on the National DNA Database in the 
context of criminal investigations and/or 
proceedings. The Act specifies when DNA samples 
and profiles can be destroyed and provides that 
the National DNA Database Strategy Board must 
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make arrangements for the database operations. 
 
In the following jurisdiction, no relevant criminal provisions could be located: Belgium, 
Bulgaria, Cyprus, Greece, Italy, Norway, Poland, Sweden, Switzerland (the offences 
pertaining to embryo research and the like are contained in sections ‘embryo research’ 
and ‘genetics in general’). Note that in most of these jurisdictions, it is very likely that 
the offences and provisions on criminal procedures relating to genetics are contained in 
secondary legislation, and as such, beyond the scope of this review. In other 
jurisdictions, for example Norway and Switzerland the offences are contained in the main 
Acts themselves, so the offences for mishandling GMOs are contained in the Act on GMOs 
etc.  
 
2.6 Patents 
 
The patent legislation across most of the 31 jurisdictions shows a large degree of 
uniformity due to the Directive 98/44/EC on the legal protection of biotechnological 
inventions. Most laws on this topic contain a near identical provision to, for example, 
section 1 of the Danish Patent Act No. 221 of 26/2/2017 which allows patents for 
biological material (including genes or gene sequences in some circumstances) and 
prohibits patents for methods of cloning humans, methods for modifying the human 
germline, use of embryos for industrial or commercial purposes and methods for 
modifying animal genetic identity which may cause disease unless there is a significant 
medical utility for humans or animals. An almost identical wording is found in most of the 
31 jurisdictions’ patent statutes.  
 
One exception is Ireland which appears not to include any specific references to genes or 
embryos in its Patents Act 1992. Austria and Sweden include the phrase ‘public order and 
morality’ as grounds for refusing patentability of an invention; and Switzerland in its 
Federal Act on Patents for Inventions (1954) provides more detail in its legislation 
specifying processes for forming hybrid organisms by using human germ cells, human 
totipotent cells or human embryonic stem cells and the entities obtained thereby; 
processes of parthenogenesis by using human germinal material and the parthenogenetic 
entities obtained thereby as processes which are not patentable.   
 
For further clarity see here the standard provisions, which are included in most of the 
laws listed in the table below. Here are the relevant contents of the Austrian Patent Law 
259/1970. The law prohibits any invention to be patented if it is deemed to violate ‘public 
order and morality’, which covers a potentially wide and discretionary area of prohibition. 
The Law further specifies that methods for cloning human beings and altering the genetic 
identity of the germ line of a human are not patentable, nor is the commercial use of 
human embryos and methods of altering the genetic identity of animals which would 
cause undue suffering to animals without a justifiable benefit to animals or humans. The 
Patent Law further specifies that the mere discovery of a constituent of a human body, 
including the sequence or partial sequence of a gene is not patentable. The prohibitions 
contained in the Patent Law may bar commercial exploitation of some gene technologies 
and limit the financial incentives for research. These provisions are fairly standard, 
except for the inclusion of violation of ‘public order and morality’ as grounds for 
unpatentability of an invention, which only appears in some jurisdictions.  
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See below for a list of the relevant patent statutes. Note that most of these are near 
identical to the Danish and Austrian statutes described above, so no notes were needed.  
Table 5. Summary of relevant patent statutes. 
COUNTRY LAW 
Austria The Patent Law 259/1970 
Belgium The Patent Law of March 28, 1984 (as amended on December 22, 
2008) 
Bulgaria The Patent Law (1993) 
Croatia The Croatian Patent Law (2003) 
Cyprus The Patent Law of 1998 (16 (I)/1998) 
Czech 
Republic 
Law N. 206/2000 on the protection of biotechnological inventions 
Denmark The Patent Act No. 221 of 26/2/2017 
Estonia The Patents Act (1994) 
Finland The Patents Act 15.12.1967/550 
France Intellectual Property Code 
Germany The Patent Law (1980) 
Greece Greek IP laws 
Hungary XXXIII Law on Patents and Protection of Inventions (1995) 
Iceland The Patent Act (1991) 
Ireland The Patents Act 1992 
Italy Patent law (Royal Decree No. 1127 of June 29, 1939, as last amended 
by Legislative Decree No. 198 of March 19, 1996) 
Latvia The Patent Law (2007) 
Lithuania The Patent Law (1994) 
Luxembourg Law of 7 April Amending the Amended Law of 20 July 1992 Amending 
the Patent System 
Malta The Patents and Designs Act (2002) 
Netherlands The Patent Act of 15 December 1994 
Norway The Patent Act (1967) 
Poland The Act of 9 May 2007 about Amending the Act on Copyright and 
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Related Rights and some other Laws  
Portugal The Industrial Property Code – Law no 36/2003 of 5 March 
Romania  Law No. 64/1991 on Patents (as amended up to Law No. 83/2014) 
Slovakia The Patent Law 435/2001 
Slovenia  Industrial Property Act (ZIL-1-UPB3) (as amended up to December 6, 
2013) 
Spain Law 10/2002 of 29 April 
Sweden Patent Act 1967 
Switzerland Federal Act on Patents for Inventions (1954) 
United 
Kingdom 
The Patents Act 1977 
 
2.7 Data Protection 
 
Most jurisdictions have comprehensive and almost identical Data Protection Acts which 
either expressly or by implication include genetic data in a category of ‘special or 
sensitive personal data’, which is afforded higher privacy protections. Generally speaking 
consent of the subject must be sought to process the genetic data in any way. It should 
be noted that the General Data Protection Regulation (‘GDPR’), which entered into force 
in May 2018, has had effect on many of the statutes discussed in this section. Many of 
the jurisdictions are still in the process of amending their legislative instruments or have 
very recently done so. For example, in Austria as of April 2018 there were several Bills 
and pending legislative proposals, which would place greater protections on genetic data 
in line with the GDPR. The key point is that genetic data must now be more heavily 
protected than was the case until recently across all the surveyed jurisdictions.     
 
See the table below for details of legislation relating to data protection and genetics.  
 
Table 6. Summary of relevant legislation on data protection and genetics. 
COUNTRY LAW NOTES 
Austria Data Protection Act  The Act does not directly reference genetic 
data but includes in the definition of sensitive 
data (which is subject to greater 
protections), ‘health data’ and data capable 
of revealing some information about a 
person’s health and racial or ethnic origin. 
Hence sensitive data would in many 
instances likely include genetic data. 
Cyprus The Personal Data 
Processing Act (Protection 
The Act covers data protection of sensitive 
personal data, which does not specifically 
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of Individuals) Law of 2001 
(138(I)/2001) 
include genetic information but does include 
health information and information relating 
to ethnicity and race, which could 
presumably include some genetic 
information. 
Czech 
Republic 
Law N. 101/2000 The law explicitly includes genetic data as 
sensitive personal information, thus 
subjecting genetic data to greater measures 
of protection. The Law further specifies the 
obligations on those storing or processing 
sensitive personal information. 
Estonia The Personal Data 
Protection Act (2007) 
The Act covers the area of protection and 
handling of personal data, including genetic 
data. Genetic data are expressly included as 
sensitive personal data and are thus subject 
to greater protections provided by most of 
the sections 12 to 42 of the Act. There are 
strict limits on how sensitive personal data 
may be processed and there is an obligation 
to register all processing of sensitive 
personal data with the relevant Authority. 
Hungary XXI Law on the Protection 
of Human Genetic Data, on 
the Rules of Human 
Genetic Testing and 
Research and Operation of 
Biobanks (2008) 
The Law aims to protect people’s genetic 
information. It provides how genetic data is 
to be handled, when it can be used for 
research and how genetic analysis can be 
carried out and provides rules for biobanks. 
Iceland The Privacy Act (2000) The Act specifies genetic information as 
sensitive personal information and hence all 
provisions governing the handling, storage 
and access to sensitive personal information 
govern genetic information and this 
information is afforded the highest level of 
protection by the law. 
Ireland The Data Protection Act 
2018 
The Act provides for the protection of 
personal data which includes genetic data 
and which is subject to a high protection 
level because it is specified as a special 
category of data. 
Italy The Code for the 
Protection of Personal Data 
(2003) 
The Code includes genetics as personal data 
and provide how a person consents, must be 
informed and when notifications are 
necessary when the genetic data is being 
used. There is a special provision on the 
handling of genetic data of bone marrow 
donors.  
Luxembourg The Law of 2 August 2002 
on the Protection of 
Individuals with regard to 
the Processing of Personal 
The Law provides for security protections of 
genetic data classified as health data, which 
is subject to higher protection than other 
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Data kinds of data. 
Portugal  The Law no 67/1998 of 26 
October on Personal Data 
Protection Act 
The Law regulates access to and handling of 
personal data the personal data includes 
genetic information. Genetic information is 
classified as sensitive personal information 
and special procedures must be employed 
when handling such data. 
Slovakia Law on the protection of 
personal data 18/2018 
The Law includes genetic information in 
personal data and genetic data is thus 
afforded a higher level of protection; and 
persons must give their consent for their 
genetic information to be processed, as per 
section 16. 
United 
Kingdom 
The Data Protection Act 
2018 
The Act regulates the protection of personal 
data, which includes genetic information. The 
Act provides more stringent protections to 
sensitive processing, which includes the 
processing of genetic data. The Act also 
limits the processing of genetic data by 
insurance providers.   
 
The jurisdictions, which are not included in the table above most likely do not directly 
mention genetics in the text of the statute and/or include data protection as regulations 
or secondary legislation, and as such, outside of the scope of this review.  
 
2.8 Other 
 
There are other notable instances of legislation covering genetics which are less common 
and provide interesting examples of jurisdictional diversity. 
 
2.8.1 Employment and genetics 
One example of genetic provisions within employment law is the Finnish prohibition on 
mandatory genetic testing of employees; neither are employers allowed to request 
results of any such test if the employee had previously undergone genetic testing as 
provided by the Finnish Act on Protection of Privacy in Working Life 13.8.2004/759. 
Similar provision is made in Article 19 of the German Genetic Testing Act. 
 
2.8.2 Insurance and genetics 
Some jurisdictions also address genetics in the insurance context. The German Genetic 
Testing Act, for example, provides in Article 18 that it is prohibited to require genetic 
data from a person in the health insurance context, but it is allowed in the contact of 
occupational disability and nursing care insurance. The Icelandic Law on Insurance 
Contracts (2004) similarly prohibits companies to use results of genetic testing and any 
associated risks of developing certain diseases to determine the insurance policy of 
clients; nor are companies allowed to request such information from people. The 
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Lithuanian Insurance Law (2003) in Article 117 also prohibits insurers to take into 
account or require any genetic data from insured persons. 
 
2.8.3 Animals and genetics 
A variety of animal-related laws touches on genetics. An example is the Slovakian Law 
against animal abuse 246/1992, which provides that experiments on animals are to be 
carried out on animals which are designated for that purpose and suited from a genetic 
perspective before any other animals. Another is the Dutch Law on Animal Testing of 12 
January 1977, which provides when animal experiments end with regards to genetically 
modified animal lines. The Animal Law of 19 May 2011 forbids changing of genetic 
material of animals solely for the purpose of enhancing their sporting performance or 
entertainment in a manner that ignores the natural barriers of sexual reproduction and 
recombination. It is also prohibited to use biotechnological techniques on an animal or an 
animal embryo without a permit. 
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3 Country summaries 
The present chapter presents the summaries of the key legislation of each of the 31 
countries analysed.  
Only the more relevant instruments and their aspects are discussed below. For a more 
comprehensive overview, which includes potentially less relevant legislative provisions, 
an on-line interactive compendium of all the retrieved legislative instruments, intended 
for public use will soon be established.  
The scope of the analysis is limited to primary national legislation and does not extend to 
local regulations, decrees or other administrative or regional and local acts. 
The search for the legislative material has been performed through national dedicated 
websites (both governmental and non-governmental) that collect the national legislation. 
Whenever possible, the search facilities of the websites have been used to retrieve the 
documentation. When this was not possible other means to identify the correct norms 
had to be identified, on a case by case basis, leading to less precise and exhaustive 
results.  
Whenever possible, the English version of the documents (both official and non-official 
translations) has been preferred. Where no English translation was identified, legislations 
were achieved in original language and then translated, using different means, including 
the European Commission translation services of DG-Translation, when needed. 
 
 
3.1 Austria 
General Outline 
Austria has a fairly comprehensive legislative regime relating to genetics, which covers 
areas of data protection, patents, criminal prosecution, genetically modified organisms as 
well as environmental protection. The legislation is broadly standard as compared across 
the European Union and the EEA; there are no significant outliers or omissions as 
compared to the rest of the block. The one notable exception is the inclusion of violation 
of ‘public order and morality’ as a ground for unpatentability of an invention which is only 
rarely repeated in patents legislation and the only comparable wording was found in the 
Swedish Patent Act.  
 
Most relevant legislation: The most directly relevant legislative instruments are the 
Patent Law, the Gene Technology Act and the Data Protection Act.  
 
Patents 
The Patent Law (Patentgesetz 1970) prohibits any invention to be patented if it is 
deemed to violate ‘public order and morality’, which covers a potentially wide and 
discretionary area of prohibition (3). The Law further specifies that methods for cloning 
human beings and altering the genetic identity of the germ line of a human are not 
patentable, nor is the commercial use of human embryos and methods of altering the 
genetic identity of animals which would cause undue suffering to animals without a 
justifiable benefit to animals or humans.(4) The Patent Law further specifies that the 
mere discovery of a constituent of a human body, including the sequence or partial 
sequence of a gene is not patentable. The prohibitions contained in the Patent Law may 
bar commercial exploitation of some gene technologies and limit the financial incentives 
                                           
(3 ) Patent Law 259/1970, art 2 
(4 ) Patent Law 259/1970, art 2 
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for research. These provisions seem fairly standard, except for the inclusion of violation 
of ‘public order and morality’ as grounds for unpatentability of an invention.  
 
Criminal context 
Austria has a number of laws which govern the handling of genetic material in the 
criminal context. The Criminal Procedure Code limits the use of genetic data collected 
from suspects and convicts to the purpose for which the data was initially collected and 
provides strict provisions as to when data should be deleted (5). The same law also 
specifies how a DNA analysis is to be carried out.  It provides that DNA is included as 
‘sensitive data’ and specifies how the data should be handled. The Security Police Act 
566/1991 provides how DNA is to be used in the identification of persons.  The police 
power is limited to utilising DNA to cases where the person is suspected of having 
committed a criminal offence, which carries a sentence of at least one year of 
imprisonment (6). 
 
The Aliens Police Act 100/2015, the Border Control Act 435/1996 and the Citizenship Law 
311/1985 provide for public authority powers in some very limited circumstances to 
check a person’s DNA to confirm their identity, especially to prove a familial relationship 
in cases of family migration (7). 
 
GMOs and genetic technology 
The Gene Technology Act implements the Council Directive 98/91/EC among others and 
regulates the use of gene technologies and GMO use and licensing. Importantly, Article 
65 outlines the limited reasons for which genetic analysis for medical purposes can be 
carried out. The enumerated purposes are to identify existing diseases and for the 
preparation to use gene therapy on the patient where the therapy is based on specific 
genetic markers. Genetic analysis can also be used to detect diseases which are based on 
a germ line mutation and to establish a predisposition for a disease, especially to 
evaluate the likelihood of a genetic disease occurring in the future where there is scope 
for prevention. The Act also specifies when genetic analysis in humans can be used for 
scientific purposes and training (8), and limits the use of gene data beyond the original 
purpose of its collection. The Act further provides details of the qualifications and 
procedures whilst handling genetic data and situations where genetic information can be 
revealed to family members. The Act also provides for when gene therapy is allowed and 
what must be satisfied before it can be administered to patients (9).  
 
The Animal Rights Law specifies when the germ line of animals may be changed via 
scientific experiments and when experimentation has to end (10). 
 
Lastly, the Genetic Engineering and Cultivation Prohibition Law 93/2015 aims to prevent 
undesirable effects of GMOs, and establishes the Advisory Council for the Coordination of 
Genetic Engineering, which is tasked with exchanging information and cooperating with 
other similar bodies on European and regional developments in the authorisation, 
monitoring and application of genetically modified organisms (11). 
                                           
(5)  Criminal Procedure Code 1975, art 75 
(6)  Aliens Police Act 100/ 2005 
(7)  Aliens Police Act 100/2005; Border Control Act 435/1996 
(8)  Gene Technology Act 510/1994, art 66 
(9)  Gene Technology Act 510/1994, arts 72, 74, 75 
(10)  Animal Rights Law Amendment Act – TVRAG, arts 2, 11 
(11) Genetic Engineering Cultivation Prohibition Law 93/2015, art 1 
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Data protection 
Austria’s Data Protection Act does not directly reference genetic data but includes in the 
definition of sensitive data (which is subject to greater protections), ‘health data’ and 
data capable of revealing some information about a person’s health and racial or ethnic 
origin (12). Hence sensitive data would in many instances likely include genetic data 
which should therefore be subject to greater protections under the Data Protection Act. 
Note that as of April 2018 there were several Bills and pending legislative proposals 
which would place greater protections on genetic data in line with the GDPR. The current 
Act provides for special regulation of use of sensitive data in scientific and statistical 
investigations which could impact genetics research (13). 
 
Environment and food safety  
The Environmental Information Act 495/1993 provides for free access to information 
regarding the environment, which includes access to information relating to genetically 
modified organisms (14). The freely accessible information appears to cover mainly the 
location and use of genetically modified organisms and disclosure of any potential risks. 
 
The Food Safety and Consumer Protection Law 13/2006 provides for measures for tracing 
and labelling of GMO foods and protection of consumers against any detrimental effects 
of GMOs (15).  
 
3.2 Belgium 
 
General Outline 
The Belgian laws which were located provide a relevant coverage of the issues 
surrounding genetics research. The most significant legislation is the Law of 11 May 2003 
on research on in vitro embryos, which outlines when research on embryos is allowed. 
 
Most relevant legislation: Law of 11 May 2003 on research on in vitro embryos  
 
Embryo research 
In Belgium, stem cell research is regulated by the "In vitro Research on Embryos" Act of 
11 May 2003 (16). Consequently, in Belgium, it is legally permitted to conduct research 
on embryos within 14 days of fertilization. The condition is that the research pursues 
therapeutic goals and knowledge about the prevention or treatment of diseases. Also 
gaining new knowledge in the areas of fertility, sterility and organ tissue transplantation 
are reasons for research on embryos in vitro if no other research methods promise 
qualitatively equivalent results. The production of embryos specifically for research 
purposes is generally prohibited, but is permitted if the existing "surplus" embryos do not 
meet the needs of the research project. The law further provides that reproductive 
cloning is prohibited, and all research projects must be submitted to the local ethics 
committee. The use of embryos for commercial purposes is likewise prohibited, as is the 
                                           
(12)  Data Protection Act 2000, art 4 
(13)  Data Protection Act 2000, art 46 
(14)  Environmental Information Act  495/1993, art 4 
(15)  Food Safety and Consumer Protection Law 13/2006, art 4 
(16)  Law of 11 May 2003 on research on in vitro embryos. 
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production of embryos in vitro for research purposes unless the purpose of the research 
cannot be achieved by research on surplus embryos. Egg fertilisation is allowed if the egg 
donor is of a legal age and has given written consent and the fertilisation is justified.   
 
GMOs 
Royal Decree regulating the deliberate release into the environment and the placing on 
the market of genetically modified organisms or products containing (2004)(17) is the 
standard GMO instruments which regulates the contained use, deliberate release and 
marketing of GMOs and GMO products. It provides for the safety and reporting 
requirements as well as the procedure for obtaining the relevant licences and penalties 
for breaches of the Decree.  
 
Animal law 
The Law on Animal Welfare provides that any invasive or non-invasive use of animal for 
experimental or other scientific purposes which may cause the animal pain, distress or 
permanent damage is not allowed unless there is some large benefit (18). This includes 
any intervention that is designed or likely to result in the birth or incubation of an animal 
in such a condition or creation and maintenance of a genetically modified animal line in 
such condition, but does not include the killing of animals solely for use their organs or 
tissues. 
 
Patents 
The Patent Law of March 28, 1984 (as amended on December 22, 2008) appears to be a 
standard European patent legislation (19). Article 4 prohibits patents for methods for 
cloning human beings, techniques for ‘splitting’ embryos aimed at creating a human 
beings; methods for modifying the genetic identity of humans; methods for modifying 
the genetic identity of animals when there is not an overwhelming medical benefit to 
humans or animals; the human body at different stages of its developments and 
elements isolated from the body.  
 
3.3 Bulgaria 
 
General Outline 
Bulgaria’s legislative coverage of topics relating to genetics is fairly comprehensive with 
the exception of genetics in the criminal context. Despite considerable effort, no primary 
legislation on this topic could be located. It is possible that the relevant provisions are 
contained in Regulations, and hence outside of the scope of this review. The most 
notable outlier is Article 8(9) in the Child Protection Act (2000) which instructs parents 
and guardians of children not to allow their children to participate in advertisements or 
other form of communications for genetically modified foods. No specific legislation 
relating to gene technologies was found in this jurisdiction.  
 
Most relevant legislation: Relevant legislation in this jurisdiction includes the Patents Act, 
Health Law and the Law on Genetically Modified Organisms.  
                                           
(17)  Royal Decree regulating the deliberate release into the environment and the placing on the market of 
genetically modified organisms or products containing GMOs (2004). 
(18)  Law on Animal Welfare. 
(19)  The Patent Law of March 28, 1984 (as amended on December 22, 2008) 
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Patents 
The patent law (1993) limits what may be subject to patent (20). Similarly to Austria, 
Bulgaria prohibits patentability for inventions where their commercial use would violate 
public order and morality, which explicitly includes methods for cloning humans, methods 
for modifying the genetic identity of human embryos and the use of human embryos for 
commercial purposes, as well as methods for genetically modifying animals where the 
effected pain is large and without any substantial benefit to humans or animals. The 
human body and its elements, including the sequence or a partial sequence of a gene, 
are not patentable but can be when an element isolated from the human body is 
obtained by a technical process even if the elements are identical to that of a natural 
element. This appears to permit patentability of gene sequences in some circumstances. 
 
Health 
The Health Law (2005) touches on genetics in healthcare and medical research (21). This 
law prohibits the use of IVF to select the sex of the baby, unless it is done to prevent a 
sex-linked genetic disease, and it is prohibited to use assisted reproduction techniques 
which aim to transmit genetic information of only one individual to the offspring. The law 
further provides for genetic treatments to prevent hereditary diseases occurring in 
children. The legislation also covers some basics relating to genetic studies and the 
required licences for any such research, as well as a provision to the effect that genetic 
laboratories may establish DNA banks for the collection and storage of genetic material 
for scientific and medical purposes. Importantly, Article 198 of the Law provides that 
medical scientific research on humans shall not be carried out with genetic engineering 
products which may lead to transmission of these changes to the offspring of the 
subjects. It appears therefore that permanent and inheritable changes in a person’s 
genetic makeup are prohibited.  
 
Animal law and environment and GMOs 
Bulgaria has numerous laws regulating the access and management of genetic 
information of animals, including fish. The Animal Law (2000) provides for the 
management of genetic resources of animals and establishes a national genetic bank 
which contains animal genetic information (22). The Act appears mainly aimed at 
agriculture and food production. The purpose of the genetic bank is to ensure biodiversity 
of livestock into the future. The Law on Fish and Aquaculture (2001) provides for safety 
measures and handling of genetic materials (eggs etc.) of fish, particularly its sale (23). 
Law on Biological Diversity (2002) specifies as one of its aims the preservation and 
conservation of the genetic diversity of plants and animals (24). Overall, in Bulgaria there 
appears to be a strong focus on the fauna and flora diversity and its protection and 
exhibits wariness in introducing GMOs into the environment as specified in the 
Environmental Protection Law (2002), whereby GMO release is expressed as a potential 
danger to the environment, animals and humans (25).  
 
                                           
(20)  Patent Law (1993) 
(21)  Health Law (2005) arts 127, 135, 138, 139, 144, 198 
(22)  Animal Law (2000) 
(23)  Law on Fish and Aquaculture (2001) 
(24)  Law on Biological Diversity (2002) 
(25)  Environmental Protection Law (2002) 
 31 
The Law on Genetically Modified Organisms (2005) is near identical to its equivalents 
across the EU and regulates the closed use of GMOs, deliberate release of GMOs as well 
as marketing of GMOs (26).  
 
Food safety and consumer affairs 
The Child Protection Act (2000) instructs parents to not allow their children to participate 
in advertisements or other forms of communication for genetically modified foods (27). 
This provision appears to be the only one of its kind located in the course of this review.  
 
3.4 Croatia 
 
General Outline 
No specific gene technology legislation could be identified for Croatia, and the legislation 
which relates to aspects of genetics is mainly focused on consumer affairs, criminal 
procedure, IVF, GMOs and patents.  
 
Most relevant legislation: The most relevant legislation is the Law on the Protection of 
Patients’ Rights (2004) which prohibits the alteration of human germ line.  
 
Patents 
The provisions of the Croatian Patent Law (2003) are broadly the same as in most EU 
jurisdictions (28). The Patent Law prohibits patents for the human body but allows for 
patentability of a gene or a segment of a gene in some circumstances. It prohibits 
patents for methods for cloning humans, modifying genetic identity of the human germ 
line, use of human embryos for commercial purposes and methods for genetically 
modifying animals where there is no substantial health benefit for animals or humans.  
 
Health laws 
The Law on the Protection of Patient’s Rights (2004) specifies that interventions directed 
at changing the human genome can only be undertaken for preventative or therapeutic 
purposes and no interventions are allowed with the view to changing the patient’s germ 
line (29).  
 
The Act on Assisted Reproduction (2012) regulates IVF, genetic counselling during 
pregnancy and prohibits certain acts such as creating genetically identical human beings 
(30). It provides for rules on donating eggs and sperm as well as embryos and the 
allowed use of these; and also establishes a central registry with information on persons 
who used IVF and for their children. The Act also prohibits using any data collected 
during any IVF procedure for any other purpose apart from aggregate statistical 
indications. It is also prohibited to select the sex of a child unless it is to prevent a sex-
linked condition and research on embryos and their alteration is generally prohibited. 
 
                                           
(26)  Law on Genetically Modified Organisms (2005) 
(27)  Child Protection Act (2000) 
(28)  Patent Law (2003)  
(29 ) Law on the Protection of Patients’ Rights (2004) art 22 
(30)  Act on Assisted Reproduction (2012) arts 4, 9, 19, 27, 37, 50, 53  
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The Law on Medicines (2013) regulates the use of GMOs in medicines and gene therapy; 
and specifies what ethical approvals are needed in those circumstances (31). In all cases 
the Central Ethics Committee must give its permission and opinion on the admissibility of 
clinical trials for gene therapy and for medicines containing GMOs.  
 
Criminal context 
The Criminal Procedure Code provides for how DNA is to be handled during and after 
criminal investigations and which persons have the authority to access the genetic data, 
when the data are to be destroyed and what consents are necessary from the subject of 
the investigation (32).  
 
GMOs, environment and food safety 
The Act on Genetically Modified Organisms (2005) is standard and very similar to other 
European legislation on GMOs (33). It specifies what licences are necessary for contained 
use of GMOs, deliberate release of GMOs as well as their placement on the market. The 
Food Act (2013) specifies that all food can be deemed unsafe on the basis of containing 
GMOs and the Croatian Food Agency is to provide reports on food safety reports on GMO-
containing food (34).  
 
The Law on Nature Protection (2013) specifies biodiversity as one of its goals and 
prohibits the introduction of GMOs into the environment without a relevant permit (35). 
The law further regulates access and use of the wildlife animal’s genetic material. 
 
 
3.5 Cyprus 
 
General Outline  
No specific legislation on gene technologies could be found, but Cyprus has extensive 
coverage of legislation relating to GMOs, IVF, environmental protection, personal data 
protection and food safety. Only limited legislation relating to the use of DNA in criminal 
contexts could be located, which indicates any other such provisions are likely contained 
in local regulations as opposed to primary legislation. The legislation described below as 
‘health laws’ is the most directly connected to genetic technologies and permitted 
activities in relation to genetics.  
 
Most relevant legislation: The most relevant instruments are the Bioethics (Establishment 
and Functioning of the National Committee) Law of 2001 (150(I)/2001) and the Medically 
Assisted Reproduction Law of 2015 (69(I)/2015). 
 
Patents 
The Patent Law of 1998 is broadly of the same character as the patent laws all across the 
EU (36). It excludes patentability of the human body and its elements, except for in 
                                           
(31)  Law on Medicines (2013), arts 14, 15  
(32)  Criminal Procedure Code (2008) 
(33)  The Act on Genetically Modified Organisms (2005) 
(34)  The Food Act (2013) 
(35)  Law on Nature Protection (2013) arts 7, 55, 88, 89 
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certain circumstances the elements, including a sequence of a gene may be patented. 
The Act further prohibits patenting of methods for human cloning, modifying the germ 
line identity of humans, using embryos for industrial or commercial purposes and 
genetically modifying animals in situations where there is no substantial medical utility 
for humans or animals.  
 
Health laws 
Cypriot law regulates IVF through the Medically Assisted Reproduction Law of 2015 
(69(I)/2015) which outlines the procedures for IVF as authorised by law and when pre-
implantation genetic diagnosis can be carried out (37). The Law prohibits sex-selection of 
embryos except for the cases where there is a high probability of the child developing a 
sex-linked genetic disease. The Law also provides for when genetic counselling is to be 
made available to prospective parents/donors and how the genetic facilities are to be run 
and inspected. 
 
The Bioethics (Establishment and Functioning of the National Committee) Law of 2001 
(150(I)/2001) establishes the National Bioethics Committee (38). The Committee 
analyses and evaluates projects relating to genetics and is also responsible for informing 
the public on its findings and monitoring implementation of the international obligations 
of Cyprus relating to genetics.  
 
Data protection 
The Personal Data Processing Act (Protection of Individuals) Law of 2001 (138(I)/2001) 
covers data protection of sensitive personal data, which does not specifically include 
genetic information but does include health information and information relating to 
ethnicity and race, which could presumably include some genetic information (39). The 
Act provides for stronger protections for sensitive data and limits the permitted uses of 
such data.  
 
GMOs 
Cyprus has a multitude of legislative instruments covering GMOs. The Biological 
Production Law of 2001 (160(I)/2001) specifies that GMO foods must be labelled as such 
and gives the relevant Minister the power to issue regulations for GMO foods (40). Both 
the Genetically Modified Organisms (Release into the Environment) Law of 2003 
(160(I)/2003) and the Genetically Modified Organisms (Limited and Contained Use) Law 
of 2004 (15(I)/2004) provide for what permits are necessary when using GMOs, the 
procedure for acquiring permits as well as safety obligations placed on those using GMOs. 
These two laws are broadly identical to those in other EU jurisdictions. The Food (Control 
and Sale) Law of 1996 (54(I)/1996) specifies that GMO-containing foods must be labelled 
as such and must be placed on separate shelves in stores, apart from other food (41).  
 
3.6 Czech Republic 
 
General Outline  
                                                                                                                                    
(36)  Patent Law of 1988 (16 (I)/1998) 
(37)  Medically Assisted Reproduction Law of 2015 (69(I)/2015) 
(38)  The Bioethics (Establishment and Functioning of the National Committee) Law of  2001 (150(I)/2001)  
(39)  Personal Data Processing Act (Protection of Individuals) Law of 2001 (138(I)/2001, arts 6, 8 
(40)  Genetically Modified Organisms (Release into the Environment) Law of 2003 (160(I)/2003)), arts 3,4,5,22 
(41)  The Food (Control and Sale) Law of 1996 (54 (I)/1996) 
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There seems to be no specific legislation targeted at genetic technologies, the most 
closely related law seems to be the Penal Code which prohibits certain acts with genetic 
data and health laws regulating IVF and genetic testing in people. Other areas addressed 
by relevant Czech laws are protection of the environment, agriculture, use of GMOs and 
data protection. Overall, fewer legislative instruments with direct relevance were located 
in this jurisdiction.  
 
Most relevant legislation: N. 227/2006, N. 40/2009, N. 227/2006, N. 202/2017, N. 
66/2013 
 
Health laws 
Law N. 202/2017 relates to specific medical services (42). It regulates genetic testing in 
patients and specifies the circumstances in which genetic testing is permitted and what 
procedure must be followed. Law N. 66/2013 which regulates the provision of medical 
services, specifies when genetic information of a person can be used and in what way 
(43).  
 
Patents 
Law N. 206/2000 on the protection of biotechnological inventions prohibits in much the 
same way as other European jurisdictions patents to be issued for procedures, which 
alter the genetic identity of animals in a way which does not cause a substantial benefit 
to human or animal health and prohibit the patentability of gene sequences in humans 
(44).  
 
Criminal context 
Law N. 227/2006 is the Penal Code which specifies certain acts as offences; these include 
handling and using human genetic information in prohibited ways (45). These prohibited 
acts relate especially to breaches of confidentiality. 
 
Environmental laws, agriculture and GMOs 
The Czech Republic has numerous laws relating to protecting the environment and GMOs. 
Law N. 148/2003 regulates the conservation and usage of genetic resources of plants 
and microorganisms important for agriculture and the food supply. The law establishes 
the National Program for storing genetic material of plants and microorganisms and 
specifies how the material is to be collected, evaluated, conserved and used. Law N. 
300/2009 regulates the introduction of seeds into the environment for agricultural 
purposes and specifies where such seeds may be genetically modified (46). Law N. 232 is 
concerned with protection of the genome of forests and establishes a National Program 
for this purpose. Law N. 60/2017 establishes a genetic registry for livestock which is 
aimed at preserving genetic diversity in the agricultural animals (47).  
 
Law N. 78/2004 regulates the use, licensing and safety of GMOs (48). The legislation is 
much the same as its equivalents in other European jurisdictions and outlines the 
                                           
(42)  Law N. 202/2017  
(43)  Law N. 66/2013  
(44)  Law N. 206/2000  
(45)  Law N. 227/2006 
(46)  Law N. 300/2009 
(47)  Law N. 60/2017 
(48)  Law N. 78/2004  
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handling procedures for GMO products, their risk evaluation and information protection; 
it has a specific section on introduction of GMOs and GMO products into the environment 
and the market, as well as provisions on the import, export and transit of GMOs and GMO 
products. Law N. 371/2016 focuses on the introduction of GMOs or GMO products on the 
market (49). 
 
Data protection 
Law N. 101/2000 is the Czech Privacy Law and in Article 4 it explicitly includes genetic 
data as sensitive personal information, thus subjecting genetic data to greater measures 
of protection (50). The Law further specifies the obligations on those storing or processing 
sensitive personal information.  
 
3.7 Denmark 
 
General Outline  
Denmark has a fairly comprehensive coverage of the most common areas of legislation 
relating to genetics. There appears to be no specific legislation addressing gene 
technologies, but many closely related instruments have been found, for example the Act 
on Cloning and Modification of Animals and the Environment and Genetic Engineering Act 
(despite its name this legislation largely covers GMO licensing). The areas covered by the 
relevant Danish legislation range from the DNA database for criminals to immigration 
provisions. No directly relevant legislation relating to genetics and health could be 
located, which indicates its existence in the form of regulations rather than primary 
legislation.  
 
Most relevant legislation: Act on Cloning and Modification of Animals, Environment and 
Genetic Engineering Act, Patent Act 
 
Patents 
The Patent Act No. 221 of 26/2/2017 is very similar to the other patent legislation 
available in other European jurisdictions (51). It provides that inventions may be 
patentable even if they concern a product consisting of a biological material which may 
be genetic information. The Act prohibits patents for methods for cloning humans, 
methods for modifying the genetic identity of human sex cells. It also prohibits the use of 
embryos for industrial or commercial purposes and methods for modifying animal genetic 
identity which may cause disease except in cases of significant medical utility for humans 
or animals.  
 
Criminal context 
The Law on processing of personal data by law enforcement authorities No. 410 of 
27/4/2017 regulates how police and associated authorities can process personal data 
(52). The legislation includes genetic data as sensitive data which is protected more 
stringently than other personal data; and cannot be used for the unambiguous 
identification of a natural person. Similarly, the Act on Establishment of a central DNA 
                                           
(49)  Law N. 371/2016 
(50)  Law N. 101/2000 
(51)  Patent Act No 221 of 26/2/2017 s1 
(52)  Law on the processing of personal data by law enforcement authorities No 410 of 27/4/2017  
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profile register No. 434 of 31/5/2000 establishes a central DNA profile register (53). The 
Act specifies the rules under which the register is to operate and who can access the 
genetic information; and limits the scope of information which can be included to that 
which is of police significance in connection with personal identification. The Act further 
provides for when data are to be deleted and when consent must be sought from the 
subjects.  
 
Environmental laws and GMOs 
Law on Benefit Sharing with the Use of Genetic Resources No. 1375 of 23/12/2012 
implements the Nagoya Protocol into Danish law and specifies when Denmark will share 
genetic resources (54). The Act also prohibits the use of traditional knowledge related to 
genetic resources held by indigenous communities if that knowledge has been acquired in 
violation of the law.  
 
The Environment and Genetic Engineering Act No.9 of 4/1/2017 regulates the space of 
GMOs (55), it clarifies when licences are necessary for the use of GMOs and provides for 
use of GMOs in closed systems, deliberate release of GMOs and marketing of GMOs, as 
well as the transport, import and transit of GMOs and specifies the risk assessments 
necessary as well as the safety precautions which must be taken. The Act on Cultivation 
of Genetically Modified Crops No. 28 of 4/1/2017 limits when GMO crops may be used 
and delegates power to the relevant Minister to issue regulations in connection with GMO 
crops (56).  
 
Animal laws 
The Act on Cloning and Modification of Animals No 478 of 15/5/2014 provides that 
cloning of animals is permitted with authorisation from the Animal Research Inspectorate 
(57). Cloning will only be allowed for the purposes of basic research, applied research 
aimed at improving the health and environment, production of breeding animals and 
producing substances of major benefit to health and the environment or education and 
training at universities and higher education institutions. Penalties are imposed for 
breaches of this Act.  
 
Immigration laws 
The Aliens Act no 1117 of 2/10/2017 provides for instances where during immigration 
proceedings genetic information can be used to identify persons and those persons’ 
relatives (58). DNA tests are permitted when an alien claims to be related to a Danish 
resident and to otherwise determine the identity of the person.  
 
3.8 Estonia 
 
General Outline 
Estonia has a comprehensive network of laws which relate to genetics. The most crucial 
instrument is the Human Gene Research Law which specifically addressed genetic 
                                           
(53)  The Act on Establishment of a central DNA profile register No 434 of 31/5/2000 
(54)  Law on Benefit Sharing with the Use of Genetic Resources No 1375 of 23/12/2012 
(55)  Environment and Genetic Engineering Act No 9 of 4/1/2017 
(56)  Act on Cultivation of Genetically Modified Crops No 28 of 4/1/2017 
(57)  Act on Cloning and Modification of Animals No 478 of 15/5/2014  
(58)  Aliens Act no 1117 of 2/10/2017 
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research and handling of genetic material and data. This law is one of the most 
comprehensive instruments found in the review addressing genetic research. Other areas 
covered by Estonian law are patents, data protection, DNA database in criminal 
proceedings as well as GMOs and environmental protection.  
 
Most relevant legislation: Human Gene Research Law (2000), Artificial Insemination and 
Embryo Protection Act (1997), Patent Act (1994) 
 
Genetic research 
The Human Gene Research Law (2000) regulates genetic research and DNA samples, 
handling and procedure (59).  It establishes a gene database and specifies the rights of 
donors and clarifies who has access to genetic information. Section 6 of the law provides 
that gene research and testing is allowed for the purpose of exploring and describing the 
relationship between genes, the environment and people’s lifestyles and exploring how to 
prevent or treat illnesses. DNA samples must be provided voluntarily. The law has 
extensive provisions specifying the rights of donors to know their genetic information, to 
order the destruction of their genetic information as well as obligations on persons 
processing the information to handle it with respect and according to the donor’s wishes. 
The law further specifies how the DNA is to be coded and de-identified for research 
purposes and prohibits any discrimination in employment relationships as a result, or on 
the basis of, a person’s genetic information. The law also prohibits any discrimination 
based on genetics in the insurance context, whereby insurance companies are prohibited 
from imposing different insurance conditions on people with different inheritance risks. 
The law also provides for the establishment of an ethics committee which scrutinises 
research.   
 
Health laws 
The Artificial Insemination and Embryo Protection Act (1997) prohibits the sex selection 
of embryos in IVF procedures except where there is a high probability of occurrence of a 
genetic disease linked to the sex chromosome (60). It is also prohibited to clone embryos 
or fuse the genetic information of embryos in order to create a cell fusion, if one of the 
embryos is a human embryo. The Medicinal Products Act (2004), specifies what permits 
clinical trials must obtain before commencement and the special conditions in 
circumstances where the proposed trial includes genetically modified organisms (61). The 
Procurement, Handling and Transplantation of Cells, Tissues and Organs Act (2015) 
regulates the handling of tissues and cells especially in the context of transplants (62).  
 
The Occupational Health and Safety Act (1999) provides that no employees shall be 
endangered by biological hazards in the workplace; biological hazards include genetically 
modified organisms (63).  
 
Patents 
The Patents Act (1994) is much the same as all the other patent legislation across the EU 
(64). It prohibits patents for processes for cloning humans, processes for modifying the 
germ line genetic identity of humans, uses of human embryos for commercial purposes, 
                                           
(59)  Human Gene Research Law (2000) 
(60)  Artificial Insemination and Embryo Act (1997) 
(61)  Medicinal Products Act (2004) 
(62)  Procurement, Handling and Transplantation of Cells, Tissues and Organs Act (2015) 
(63)  Occupational Health and Safety Act (1999) 
(64)  Patents Act (1994) 
 38 
processes for modifying the genetic identity of animals which are likely to cause them 
suffering without any substantial benefit to health of humans or animals. 
 
Data protection 
The Personal Data Protection Act (2007) covers the area of protection and handling of 
personal data, including genetic data (65). Genetic data are expressly included as 
sensitive personal data and are thus subject to greater protections provided by most of 
the sections 12 to 42 of the Act. There are strict limits on how sensitive personal data 
may be processed and there is an obligation to register all processing of sensitive 
personal data with the relevant Authority.  
 
Criminal context 
The Forensic Examination Act (2001) establishes a National DNA Database for storing 
and collecting DNA of prisoners and suspects in criminal matters (66). The law specifies 
who and when can access the DNA information and when the information is to be 
destroyed. The Imprisonment Act (2000) provides for the way prisoners’ DNA samples 
are to be handled (67). Each person admitted to prison shall have a DNA sample collected 
for the purposes of identification, detection and prevention of offences. This DNA will be 
stored in the State DNA Register.  
 
GMOs 
The Contained Use of Genetically Modified Micro-organisms Act (2001) and the Release 
into Environment of Genetically Modified Organisms Act (2004) are the standard GMO 
laws which regulate licensing of the use of GMOs and provide for use of GMOs in 
contained spaces, deliberate release of GMOs and marketing of GMOs (68). The laws 
provide for GMO export, import and transit as well as the required safety measures, 
reporting obligations and what information regarding the use of GMOs by individuals (be 
they companies or natural persons) must be publicly available.  
 
Environmental laws 
The Nature Conservation Act implements the Nagoya Protocol on Access to Genetic 
Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization to 
the Convention on Biological Diversity, Regulation (EU) No 511/2014 of the European 
Parliament and Council on compliance measures for users of the Nagoya Protocol in the 
Union, which must be followed (69). 
 
3.9 Finland 
 
General Outline 
Finland has numerous laws relating to genetics on many topics varying from biobanks, 
food safety, penal provisions, paternity testing, GMOs and medical research. Notable law 
is the Biobank Law, which establishes a biobank for storage of human tissue samples as 
                                           
(65)  Personal Data Protection Act (2007)  
(66)  Forensic Examination Act (2001) 
(67)  Imprisonment Act (2000) 
(68)  Contained Use of Genetically Modified Micro-organisms Act (2001); Release into Environment of Genetically 
Modified Organisms Act (2004) 
(69)  Nature Conservation Act (2004)  
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well as the Medical Research Act which specifies that an ethics committee must give 
approvals for research projects. Another outlier is the prohibition for employers to require 
or know results of genetic tests of their employees as per the Act on the Protection of 
Privacy in Working Life.  
 
Most relevant legislation: Medical Research Act, Biobank Law, Gene Technology Act and 
Patents Act. 
 
Health and social laws 
The Medical Research Act specifies that an ethics committee must approve research 
proposals and outlines which factors the committee is to consider in deciding on an 
application (70). The Act further specifies that the ethics committee has a longer time 
period for its decision when the application relates to gene therapies and /or genetically 
modified organisms. The Biobank Law establishes a biobank for storage of human tissue 
samples. The Biobank law does not directly address the genome or DNA but is sufficiently 
closely related to warrant a short mention. It regulates how samples collected from 
humans are to be stored and handled. It is also meant to protect the privacy and control 
of patients/subjects over the collected samples (71).  
 
The Act on the Protection of Privacy in Working Life prohibits employers to require 
employees to undergo genetic testing or request results of any genetic tests the 
employees have had previously. The Law on Genetic Research regulates paternity 
investigations and provides for when such test can be authorised. The Paternity Act 
further specifies when DNA testing can be performed to identify the father of a person 
and where such tests can be performed without the consent of the potential test subject 
(potential or suspected father).  
 
Patents 
The Patents Act is much the same as essentially all the European patent legislation (72). 
It prohibits patents for cloning of humans, processes for modifying the germ line of 
humans, commercial uses of human embryos and processes for modifying the genetic 
identity of animals which is likely to cause them suffering without any substantial medical 
benefit to humans or animals.  
 
GMOs 
The Gene Technology Act aims to promote safe use and development of genetic 
engineering and to protect human and animal health (73). The Act establishes the Genetic 
Engineering Board which oversees the obligations of persons using GMOs. The Act 
provides for licensing for the use of GMOs in closed space, their deliberate release as well 
as marketing of GMOs or GMO products.  It outlines reporting obligations, safety 
measures and risk assessments which have to be in place in order to obtain a GMO use 
licence.  
 
Criminal context 
                                           
(70)  Medical Research Act 9.4.1999/448, s10d 
(71)  Biobank Law 30.11.2012/688 
(72)  Patents Act 15.12.1967/550, ss1, 1b, 3a 
(73)  Gene Technology Act 17.3.1995/377  
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The Penal Code specifies offences related to genetics (74). It is an offence to clone a 
human, altering and generating human germ cells and animal genetic material and the 
generation of a human by combining embryos. These offences are punishable by 
imprisonment of up to 2 years. It is also prohibited to intentionally spread GMOs in 
violation of the Gene Technology Act and export GMOs without a licence.  
 
The Coercive Measures Act provides for situations when DNA can be collected from 
criminal suspects and specifies how the samples and any resulting data are to be 
handled, stored and destroyed (75).  
 
Immigration 
The Aliens Act provides that DNA analysis may be used to prove a family relationship 
between persons in the context of immigration proceedings (76). The Act further provides 
how such analysis is carried out, what happens with the data afterwards and what safety 
measures must be in place for a sample collection.  
 
Environmental laws, agriculture and food safety 
The Seed Trade Law limits the use of GMO seeds in Finnish agriculture and provides that 
there has to be a register of the verities of seeds, with a special section for GMO seeds 
(77). Similarly the Law on Trade in Forest Reproductive Material prohibits and limits the 
GMO material which is to be used in forests (78).  
The Food Act implements the Regulation EC No 1829/2003 of the European Parliament 
and of the Council on genetically modified food and feed. It also implements the 
Regulation (EC) No 1830/2003 of the European Parliament and of the Council on the 
traceability and labelling of genetically modified organisms and traceability of foods and 
feed products produced from genetically modified organisms and amending Directive 
2001/18/EC (79). 
 
3.10 France 
 
General Outline 
Most of the relevant provisions are contained in the Public Health Code which provides for 
when medical genetic research can be carried out and what provisions, namely ethical 
considerations, must be considered and abided by. Other than that the French Codes 
cover environmental, penal as well as agricultural aspects as related to genetics.  
 
Most relevant legislation: Public Health Code, Penal Code and Bioethics Law 
 
Health laws 
                                           
(74)  Penal Code 19.12.1889/39, ch22 art 4, ch34 art 4, ch44 art 9, ch48 art 1 
(75) Coercive Measures Act 22.7.2011/806 
(76)  Aliens Act 30.4.2004/301 
(77)  Seed Trade Law 4.8.2000/728 
(78)  Law on Trade in Forest Reproductive Material 5.4.2002/241 
(79)  The Food Act 13.1.2006/23 
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The Public Health Code is the most significant legislative instrument with respect to 
genetics identified in the review (80). It contains provisions on genetic counselling, when 
such counselling is to be provided and what qualifications genetic counsellors must have. 
It further defines what genetic characteristics mean and what is genetic identification. 
The Code also regulates gene therapy preparations and xenogeneic cell therapy 
preparations and importantly, Articles R1125-7 to R1125-13-1 regulate genetic research. 
The Code also provides for when prenatal and pre-implantation diagnosis can be carried 
out and who is qualified to perform the procedures; and it also regulates the examination 
of genetic characteristics by DNA fingerprinting for medical purposes.  
 
The related Law on Bioethics which is also contained in the Public Health Code specifies 
when abortions are permitted and when research on genetics can be performed (81). As 
per Article L2151-2 in vitro design or cloning of human embryos for research purposes is 
prohibited, as is the creation of transgenic or chimeric embryos. Generally speaking as 
per Article L2151-5 research on human embryos, embryonic stem cells and stem cell 
lines is prohibited. However, such research can be permitted if the scientific relevance of 
the research project is established, when the research is likely to allow major medical 
progress and the research cannot be performed any other way without the use of human 
embryos, embryonic stem cells or stem cell lines. Any such projects must be authorised 
by the Biomedicine Agency and adhere to the ethical codes promulgated by the Agency. 
The Article also specifies which embryos may be used for such research.  
 
Criminal context 
The Penal Code outlines numerous offences related to genetics when a person breaches 
provisions relating to examination of a person’s genetic characteristics and breaches 
provisions of biomedical ethics (82). The Code also provides and establishes the national 
automated DNA file and provides how it shall be operated and who has access to the 
information thereby contained.  
 
Environmental laws 
The Environmental Code contains the standard GMO legislative provisions on the 
contained use of GMOs (83), the deliberate release of GMOs and the marketing of GMOs; 
further detail can be found in the Law on Genetically Modified Organisms which regulates 
the licencing of the use of GMOs (84). The Code also specifies when GMO plants can be 
used, when seeds and seedlings containing GMOs can be planted and provides for 
protection of the environment and biodiversity of the local fauna. The law on future of 
agriculture, food and the forest specifies what role GMOs have to play in the future; and 
the Law prohibiting the cultivation of genetically modified corn varieties prohibits the 
cultivation of GMO corn and maize.   
 
3.11 Germany 
 
General Outline 
Germany has a significant number of laws which touch on genetics, with the Embryo 
Protection Act being the most relevant for present purposes.  
                                           
(80)  The Public Health Code 
(81)  Law on Bioethics 
(82)  Penal Code 
(83)  Environmental Code  
(84)  Law on Genetically Modified Organisms 
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Most relevant legislation: Embryo Protection Act (1990), Patents Act (1980) and the 
Genetic Testing Act (2009) 
 
Patents 
The Patent Law (1980) is a standard patent legislation comparable to the other European 
acts on patents (85). The Law prohibits patents for methods for cloning humans, 
modifying the germ line of humans and using human embryos for commercial purposes 
as well as for methods for genetic modification of animals in a way capable of causing 
suffering without a substantial medical benefit to humans or animals. 
 
Embryo research and health law 
The Embryo Protection Act (1990) is the most significant legislative instrument located in 
the German jurisdiction review (86). It prohibits selection of embryos on the basis of sex 
except for cases where it is to prevent Duchenne muscular dystrophy or a similarly 
serious sex-linked genetic disease.  The qualifying diseases must be so considered by the 
appropriate national body. The Act regulates the provision of pre-implantation genetic 
diagnosis, and in Article 3a it prohibits the genetic examination of the cells of an embryo 
in vitro prior to intrauterine transfer; breach of these provisions is an offence. 
Preimplantation diagnosis is allowed if the parents have a high risk of a serious 
hereditary disease and the patient must be informed of all the possible consequences of 
the procedure and an ethics committee must approve the procedure. The Act in Article 5 
strictly prohibits the alteration of the human germ line and provides that any breaches of 
the provision are punishable by up to 5 years in prison. There are some exceptions to the 
prohibition if the cell is not used for fertilisation and not transferred to an embryo, foetus 
or a human.  The Act in Article 6 further provides that it is prohibited to clone an embryo 
and place any such embryo into the womb.  In Article 7 the Act prohibits creation of 
chimera and hybrid formation and placing any such creations into a womb.  
 
The Infection Protection Act (2000) regulates epidemiological surveillance and includes a 
special provision to provide for cases where human genetic information is involved (87), 
in which case measures must be taken to avoid the identification of the data subject. The 
Medicines Act (2005) specifies the procedure for getting an Ethics Committee approval 
for medicines and provides for a special regime and extends time for the Committee to 
decide when the drugs or therapies are gene therapies or contain genetically modified 
organisms (88).  
 
The Genetic Testing Act (2009) regulates genetic testing in humans (89). The Act provides 
when and how genetic testing can be performed and how any collected genetic 
information and samples are to be handled. It also prohibits discrimination based on 
genetic characteristics in all contexts of life as well as prohibits discrimination based on 
the refusal to take a genetic test. The Act provides circumstances in which genetic 
counselling should be provided to subjects and how results of tests are to be 
communicated, as well as how quality of the test is to be assured. Furthermore, the Act 
provides that it is prohibited to require genetic data from a person in the health 
insurance context, but it is allowed in the contact of occupational disability and nursing 
                                           
(85)  Patent Law (1980) No 1/1981  
(86)  The Embryo Protection Act (1990) No 69/1990  
(87)  Infection Protection Act (2000) No 33/2000  
(88)  Medicines Act (2005) 
(89)  Genetic Testing Act (2009) No 50/2009 
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care insurance. The Family Law Procedural Law (2009) specifies when samples of DNA 
can be taken and compared in the context of determining familial relationships.  
 
Criminal context 
The Code of Criminal Procedure (1987) provides for how DNA is to be used in the context 
of criminal investigations (90), it limits the scope of genetic analysis which can be 
performed on samples and specifies how DNA samples can be collected and when 
consent for collection is not necessary.  
 
GMOs 
The Genetic Engineering Act (1993) implements the EU Council Directive 90/219 EEC of 
23 April 1990 on the contained use of GMOs (91), it specifies how licensing and use of 
GMOs for contained use works and when GMOs can be placed on the market, as well as 
outlining the safety requirements necessary to obtain a licence. The EC Genetic 
Engineering Implementing Act (2004) provides for monitoring, labelling and processing of 
GMO foods and specifies when food items can be labelled as ‘produced without the use of 
genetically modified food’ (92). 
 
Environmental laws, animal law and agriculture 
Germany has an abundance of laws relating to the environment and agriculture which 
touch on genetics. The Seed Traffic Law (2004) regulates the marketing and handling of 
plant materials and provides for special treatment of GMO seeds and seedlings (93). The 
Animal Breeding Law (2006) aims to obtain and maintain diversity of animals and 
provides for measures to monitor the genetic diversity of livestock populations and the 
internal diversity of animal breeds (94). The Federal Nature Conservation Act (2009) 
provides for what permits are necessary to release wildlife into the environment but 
specific regime is in place for animals being released to the area of their genetic origin 
(95).  
 
3.12 Greece 
 
General Outline 
The Greek laws on the genome have proven extremely difficult to locate due to the 
author’s inability to speak Greek and the lack of any in-text search function on the Greek 
law site. The laws which could be located cover topics of environment protection and 
biodiversity and IVF. 
 
Most relevant legislation: Law 3305/2002 on Medical Support in Human Reproduction and 
Law 3305/2005 Applying Medically Assisted Reproduction – both laws were amended by 
Law 4272/2014 on Human Transplants, Mental Health and Medical Assisted 
Reproduction.   
 
                                           
(90)  Code of Criminal Procedure (1987)  
(91)  Genetic Engineering Act (1993) No 67/1993  
(92)  EC Genetic Engineering Implementing Act (2004) No 29/2004  
(93)  Seed Traffic Law (2004) No 37/2004  
(94)  Animal Breeding Law (2006)  
(95)  Federal Nature Conservation Act 2009 No 51/2009 
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Health Laws 
The Law 3089 on Medical Support in Human Reproduction introduced a new chapter to 
the Greek Civil Code, covering when permits can be obtained for women to undergo IVF 
and whose sperm can be used etc.(96). The legislation also provides that when there is a 
high risk of an inherited disease, embryos may be selected in order to avoid the inherited 
disease from occurring (Article 1455). The legislation does not directly address genetics 
or embryo research. 
 
The Law 3305 Applying Medical Assisted Reproduction imposes strict conditions for 
Medically Assisted Reproduction, stipulating that it is only to be employed when it is 
necessary from a medical perspective (i.e. inability to procreate without MAR or the high 
risk of an inherited disease) and the interested female individual is under 50 years old. It 
contains an extensive definitions section of terms such as cryopreservation of gametes, 
zygotes etc. (97). The legislation operates to set up biobanks for the storage of genetic 
information and embryos as well as outline the principles of bioethics to be employed 
when performing IVF. The legislation also covers when pre-implantation genetic diagnosis 
can be performed. Further it also governs research on cells and embryos which are not 
destined for pregnancy. Research can be carried out to expand human knowledge and to 
improve diagnosis and treatment methods for infertility as well as contraception, to 
develop and control treatment techniques for genetic diseases and abnormalities and to 
study the biology of embryonic cells and their possible therapeutic uses. A licence is 
necessary for any such research. The law also creates criminal offences for the cases 
where acts are committed that increase the risks connected with Medically Assisted 
Reproduction (e.g. deficient medical procedures, disregarding the prescribed by law age 
limits etc.). 
 
Law 4272, to the extent that it amends the previous two legislative instruments, was 
enacted in the interest of clarifying ‘vague or problematic’ provisions in them and ensure 
that they respond to the challenges of applying Medically Assisted Reproduction in 
practice. The main rationale was to enhance the protection afforded to the (female) 
individual seeking to give birth by MAR and the child that will be born, while also 
considering the grave difficulties faced by medical scientists involved in this activity. The 
main amendments include the possibility of extending the duration of cryopreservation of 
genetic materials in case no communication with the interested parties is possible (article 
14), the legal power to donate gametes without the consent of one’s partner / spouse 
(article 15), a set of administrative changes meant to streamline the operation of MAR 
Units and Biobanks (articles 18, 19) and a reduction to the criminal sentence imposed to 
those who participate in selling or purchasing genetic materials (article 20).   
 
One should also note the role of the National Authority on Medically Assisted 
Reproduction within the Greek regulatory environment. Their published framework-
decisions, mainly 170/2008, 670/2008, 1287/2008 and 2683/2014, have been 
instrumental in providing authoritative guidance on the above legislative instruments for 
medical practitioners.  
 
Environmental protection and biodiversity 
The Law 3208 on the Protection of Forest Ecosystems provides in Article 19 that 
biodiversity of forests is one of the aims of the legislation (98). The Law 3937 of 15 March 
                                           
(96)  Law 3089 on Medical Support in Human Reproduction 
(97)  Law 3305 Applying Medical Assisted Reproduction. 
(98)  Law 3208 on the Protection of Forest Ecosystems. 
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2011 on Biodiversity and other Aspects of Conservation provides for the measures to 
achieve biodiversity in nature (99).  
 
3.13 Hungary 
 
General Outline 
The laws relating to genetics are fairly extensive in Hungary. The most directly relevant 
legislation is the XXI Law on the Protection of Human Genetic Data, on the Rules of 
Human Genetic Testing and Research and Operation of Biobanks (2008). The areas 
covered by relevant legislation cover criminal, data protection, environmental protection 
as well as health laws, agriculture and patents. 
 
Most relevant legislation: XXI Law on the Protection of Human Genetic Data, on the Rules 
of Human Genetic Testing and Research and Operation of Biobanks (2008) 
 
Patents 
XXXIII Law on Patents and Protection of Inventions (1995) limits the patentability of 
parts of the human body and specifies that medical or surgical procedures for treatments 
of humans or animals as well as diagnostic procedures for the human body shall not be 
considered industrially applicable (100). This Act appears to be missing the prohibition on 
patentability present in many other patent legislations around Europe. There seems to be 
no prohibition on cloning, human embryo commercial applications or the like. It must be 
noted that this could be as a result of inadequate translation of the original text and 
hence not because of a real omission in the legislation.  
 
Genetic research and health laws 
XXI Law on the Protection of Human Genetic Data, on the Rules of Human Genetic 
Testing and Research and Operation of Biobanks (2008) aims to protect people’s genetic 
information (101). It provides how genetic data is to be handled, when can it be used for 
research and how genetic analysis can be carried out and provides rules for biobanks. 
Genetic testing can be performed for prevention, diagnostic, therapeutic or rehabilitation 
purposes and solely on the basis of medical interest. People who are in possession of 
genetic data have a responsibility to protect the data. The law specifies how people are 
to be notified of genetic test results and what consent must be given before any testing 
is done. Genetic data are to be used mainly only for the purposes for which they were 
collected, but in limited circumstances this can be extended. Genetic studies can use de-
identified genetic data to determine the distribution of genetic variants between 
individuals.  
 
The LXXIX Law on the Protection of Foetal Life (1992) regulates the provision of 
abortions and aims to protect foetal life (102). It provides for the services of genetic 
counsellors and how these services feed into the assessment of permitted abortions. 
Pregnancies may be aborted until the 20th week or later if there is too great a genetic risk 
to the health of the foetus. The CLIV Law on Health (1997) also provides for other 
                                           
(99)   Law 3937 of 15 March 2011 on Biodiversity and other Aspects of Conservation. 
(100)  XXXIII Law on Patents and Protection of Inventions (1995)  
(101)  XXI Law on the Protection of Human Genetic Data, on the Rules of Human Genetic Testing and 
Research and the Operation of Biobanks (2008) 
(102)  LXXIX Law on the Protection of Foetal Life (1992) 
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instances where genetic counselling is made available especially to women during 
pregnancy and before a pregnancy (103).  
 
GMOs 
Under Hungary’s Basic Law, Article XX, Hungary can enforce the right to physical and 
mental health by assisting agriculture with GMOs (104). The XXVII Law on Genetic 
Engineering (1998) is a standard GMO law which provides for the licencing and regulation 
of contained use of GMOs (105), deliberate release of GMOs and placing GMOs or GMO 
products on the market. It further, specifies safety requirements, import, transport and 
transit permit requirements and risk assessments and reporting obligations on users of 
GMOs.  
 
Criminal context 
The LXVI Law on the Registration of Citizen’s Personal Data and Address (1992) provides 
for DNA procedures in criminal context (106). It specifies when DNA samples can be taken 
from suspects or convicted persons, how and when DNA samples must be registered and 
how DNA can be shared with other EU countries. The Law also provides for how long DNA 
is kept in the database and how it is to be stored.  
 
Environmental laws, agriculture and food safety 
The CXIV Law on Livestock Breeding (1993) regulates the quality of livestock (107). It 
provides that the genetic information of livestock must be of marketable quality. The 
statute also aims to promote genetic diversity in livestock. It also provides for the 
protection of endangered species and their genetic information.  
 
The LII Law on the Protection of Nature (1996) regulates the protection of nature (108). It 
forbids the artificially modification of the genetic stock of wild animals. It also specifies 
that it is forbidden to import genetically modified organisms and introduce them into the 
wild without appropriate authorisations.   
 
3.14 Iceland 
 
General Outline 
Laws of Iceland provide a comprehensive coverage of issues relating to genetics and 
cover topics such as insurance, privacy law, inheritance, animal welfare, DNA police 
database, IVF and use of embryos for stem cell research as well as GMOs, Patents and 
Food Safety. The most significant legislation is the Law on Artificial Fertilisation and the 
Use of Human Embryos and Embryos for Stem Cell Research (1996). Interesting outliers 
are the laws on inheritance whereby falsely claiming a genetic relationship with someone 
for the purpose of claiming their inheritance is an offence according to the Law 
Inheritance (1962). 
 
                                           
(103)  CLIV Law on Health (1997)  
(104)  Hungary’s Basic Law  
(105)  XXVII Law on Genetic Engineering (1998)  
(106)  LXVI Law on the Registration of Citizen’s Personal Data and Address (1992) 
(107)  CXIV Law on Livestock Breeding (1993) 
(108)  LIII Law on the Protection of Nature (1996)  
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The most relevant legislation: Law on Artificial Fertilisation and the Use of Human 
Embryos and Embryos for Stem Cell Research (1996) 
 
Health laws and embryo research  
The Law on Counselling and Education Regarding Sex, Childbirth and on Abortion and 
Sterilisation (1975) provides as one of the reasons for abortion when the foetus is at risk 
of serious genetic diseases and that abortion should always be allowed after the standard 
16 weeks if there is a high probability of genetic defects in the foetus (109). The Law 
further provides that sterilisation of a person is allowed when the person’s children would 
be at a high risk of a genetic disease.   
 
The Law on Artificial Fertilisation and the Use of Human Embryos and Embryos for Stem 
Cell Research (1996) provides that in cases where there is a risk of severe genetic 
diseases, the use of donor cells is permitted in IVF; and cells intended to be used for IVF 
cannot be destroyed (110). Embryos may be used for research in certain circumstances 
when they are not intended for IVF and the research would yield useful scientific and 
medical knowledge, but all projects must be permitted by the Bioethics Committee. It 
must also be shown that there is no other way to conduct the research. It is prohibited to 
cultivate or produce embryos solely for research purposes and have embryos for more 
than 14 days outside the body or once the primitive streak has developed. It is also 
prohibited to perform nuclear transfer for reproductive purposes (cloning) and transplant 
human embryos into animals.  
 
Patents 
The Patent Act (1991) is a standard European legislation relating to patents with 
essentially identical prohibitions on patentability as most of the jurisdictions above and 
below (111). The Act prohibits patents for methods of cloning humans, modifying the 
human germ line, commercial uses for human embryos and changing animal genes 
without a substantial medical benefit to humans or animals.  
 
Other 
The Law on Inheritance (1962) brings genetics into the context of inheritance and Article 
25 creates a criminal offence for where a person fraudulently claims to be in a genetic 
relationship in order to get their inheritance (112). The Law on Insurance Contracts (2004) 
prohibits companies to use results of genetic testing and any associated risks of 
developing certain diseases to determine the insurance policy of clients, nor are 
companies allowed to request such information (113).  
 
Privacy and data protection 
The Privacy Act (2000) specifies genetic information as sensitive personal information 
and hence all provisions governing the handling (114), storage and access to sensitive 
personal information govern genetic information and this information is afforded the 
highest level of protection by the law.  
                                           
(109)  Law on Counselling and Education Regarding Sex and Childbirth and on Abortion and Sterilisation 
(1975)  
(110)  Law on Artificial Fertilization and the Use of Human Embryos and Embryos for Stem Cell Research 
(1996)  
(111)  Patent Act (1991)  
(112)  Law on Inheritance (1962) 
(113)  Law on Insurance Contracts (2004)  
(114)  Privacy Act (2000)  
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Criminal context 
The Law on Genetic Register of Police (2001) establishes the Icelandic DNA database for 
storing and comparing DNA of suspects and convicts (115). The Law specifies when and 
how DNA can be collected, when must it be destroyed, who can have access to the 
information; and provides that the Data Protection Authority shall ensure proper 
administration of the database and protect the privacy of the individuals whose 
information is contained in the database.  
 
GMOs, environmental, agricultural and animal laws 
The Law on Import of Animals (1990) provides for import of animal genetic material 
(eggs and sperm) and provides for regulations on ensuring the health of any imported 
genetic material.(116) The Animal Diseases Act and Prevention of Animal Disease (1993) 
includes prevention of genetic diseases in its aim to prevent animal disease (117). The 
Veterinary and Animal Health Act (1998) regulates the genetic quality of imported 
livestock and the Law on Animal Welfare (2013) prohibits genetic engineering of animals 
where it would change the characteristics of the animal in such a way so as to 
detrimentally affect the animal’s health or behaviour as well as their offspring and if it 
were to reduce the ability of the animal to show ‘normal’ behaviour (118).  
 
The Act on GMOs (1996) is a standard GMO statute and regulates the contained use, 
deliberate release and marketing of GMOs (119). The Act specifies what licences are 
necessary, what safety measures must be taken and what powers the relevant 
authorities have to inspect the users of GMOs. The Food Act (1995) gives the Minister the 
power to issue regulations with respect to packing, labelling, ingredients, internal 
processes, inspections and packing of genetically modified foods (120).  
 
3.15 Ireland 
 
General Outline 
There seems to be a notable absence of legislation governing gene editing and research 
on embryos (see here for an article  for more detail). The legislation relating to genetics 
covers environmental protection, patents, genetic testing, animal welfare and DNA 
samples in the criminal context as well as data protection. 
 
Most relevant legislation: The Disability Act 2005 
 
Health laws 
The Disability Act 2005 governs genetic testing in persons and provides that testing shall 
not be carried out on a person unless it is not prohibited by law and the consent of the 
data subject has been obtained in accordance with the Data Protection Act (121). The 
                                           
(115)  Law on Genetic Register of Police (2001)  
(116)  Law on the Import of Animals (1990)  
(117)  Animal Diseases Act and Prevention of Animal Disease (1993)  
(118)  Veterinary and Animal Health Act (1998); Law on Animal Welfare (2013) 
(119)  The Act on GMOs (1996)  
(120)  Food Act (1995)  
(121)  Disability Act 2005  
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subject of the genetic testing must be provided with all relevant information prior to the 
genetic sample being collected.  
 
Patents 
The Patents Act 1992 seems substantially different to many of the other patent statutes 
in this report (122). The Act does not specifically refer to genetics or other genetic-related 
issues, but the Act would nonetheless be relevant and shows the potential gaps in 
legislation where    genetics are not specifically addressed.  
 
Criminal context 
Criminal Justice (Forensic Evidence and DNA Database System) 2014 establishes the 
DNA database (123), as well as the framework for when DNA samples can be taken from 
suspects and the procedures for collection, storage and handling of the samples and any 
resulting data.  
 
GMOs, environmental and animal laws 
The Environmental Protection Agency Act 1992 gives the Minister power to issue 
regulations relating to GMOs and such regulations have been issued (S.I. No 500/2003 
Genetically Modified Organisms (Deliberate Release) Regulations 2003 (124). 
 
The Animal Health and Welfare Act 2013 provides that the Minister may direct that an 
animal may be killed or destroyed where the Minister is of the opinion that it is because 
of its genetic makeup particularly susceptible to disease (125).  
 
Data protection 
The Data Protection Act 2018 provides for the protection of personal data which includes 
genetic data and which is subject to a high protection level because it is specified as a 
special category of data (126).  
 
3.16 Italy 
 
General Outline 
The laws of Italy relating to genetics are fairly varied, but only few of the available 
instruments engage with the subject deeply. Many of the located laws relate to 
agriculture and implementation of international agreements. There are laws govern the 
protection of privacy, as well as the use of embryos in research and the protection of the 
environment and GMOs. It is highly likely that many of the criminal and GMO-related 
provisions are included in regional regulations and hence outside of the scope of this 
review. 
 
                                           
(122)  Patents Act 1992  
(123)  Criminal Justice (Forensic Evidence and DNA Database System) 2014  
(124)  Environmental Protection Agency Act 1992  
(125)  Animal Health and Welfare Act 2013  
(126)  Data Protection Act 2018  
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Most relevant legislation: Law of 19th February 2004 n 40 – Rules on medically assisted 
reproduction 
 
Embryo research 
The Law of 19th February 2004 n 40 – Rules on Medically Assisted Procreation provides 
that couples with genetically transmissible diseases can utilise IVF (127). It is prohibited to 
engage in behaviour which may lead to cloning a person and this act is punishable by 10-
20 years in prison and a substantial monetary penalty. As per Article 13, experimentation 
on embryos is forbidden, any form of eugenic selections of embryos or gametes through 
any techniques aimed at altering the genetic information of the embryo or gamete or 
‘designing’ the genetic characteristics of an embryo is also forbidden. Note that Article 13 
has been updated by a constitutional court decision (Sentenza 21 October – 11 
November 2015, n.229 published in Gazzetta Ufficiale, 1a Serie Speciale n. 46 of 
18/11/2015,) which allows for selection of embryos in situations where the selection of 
an embryo is targeted at avoiding or preventing implantation of an embryo which is 
affected by a genetically transmitted disease. 
 
Data protection 
The Code for the Protection of Personal Data (2003) includes genetics as personal data 
and provide how a person consents (128), must be informed and when notifications are 
necessary when the genetic data is being used. There is a special provision on the 
handling of genetic data of bone marrow donors.  
 
GMOs, agriculture and environment 
The Law of 22nd November 2004, n. 279 – Urgent provisions to ensure coexistence 
between the forms of transgenic, conventional and biological agriculture, provides for 
how transgenic crops can co-exist with standard crops (129). The Environmental rules – 
Legislative Decree of 3 April 2006, no 152 (note this is often referred to as the 
Environmental Code but is not formally a code) identify uses for GMOs in protecting the 
environment, including the use of GMOs to improve the soil (130). The Law of 1st 
December 2015, n 194 – Provisions for the protection and enhancement of biodiversity of 
agricultural and food interests aims to protect agriculture and food sources from genetic 
pollution and loss of genetic heritage (131). It specifies which organisms are local and 
establishes networks to support the development of the local agricultural resources.  
 
Other 
Many of the listed laws contained in the individual jurisdiction report relate to Italy’s 
implementation of international agreements; these include the implementation of the 
Biodiversity Convention, the Cartagena Protocol, International Resource Treaty on 
Phytogenetics and the European Convention for the Protection of Minors Against Sexual 
Exploitation and Abuse (132).  
                                           
(127)  Law of 19th February 2004, n 40 – Rules on medically assisted procreation  
(128)  Code for the Protection of Personal Data (2003)  
(129)  Law of 22nd November 2004, n 279 – Urgent provisions to ensure coexistence between the forms of 
transgenic, conventional and biological agriculture  
(130)  Environmental rules – Legislative Decree of 3 April 2006, no 152  
(131)  Law of 1st December 2015, n 194 – Provisions for the protection and enhancement of biodiversity of 
agricultural and food interests  
(132)  Law of 14th February 1994 n. 124 – Ratification and implementation of the biodiversity convention, 
with annexes made in Rio de Janeiro on 5 June 1992; Law of 15th January 2004, n. 27 – Ratification 
and implementation of the Cartagena Protocol on prevention of biotechnological risks related to the 
Diversity Convention with appendices adopted in Montreal on 29 January 2000; Law of 6 April 2004, n. 
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3.17 Latvia 
 
General Outline 
The laws of Latvia on the genome are sophisticated and engage with the subject. Latvia 
has one of the most directly targeted legislations on the topic, the Human Genome 
Research Law which establishes a comprehensive legislative framework for governance of 
genetics research in the country. There are also laws on the environment, criminal 
procedure, sexual health, environmental protection and GMOs which engage with 
genetics.  
 
Most relevant legislation: Human Genome Research Law (2003) 
 
Genome research and health law 
The Sexual and Reproductive Health Law (2002) regulates IVF and provides when and 
how it is available; and it also specifies the rights of donors (133). The Law prohibits 
cloning of humans.  
 
The Human Genome Research Law (2003) is perhaps the most comprehensive legislation 
located throughout the review (134). Its purpose is to regulate the establishment and 
operation of a single genome database of the Latvian population for genetic research and 
ensures the voluntary nature and confidentiality of gene donation. The Law establishes 
the Genome Research Board which has the authority to examine projects and concepts 
related to genetic research, and facilitate provision of public information about such 
research. There are strict limits on which bodies are allowed to process genetic 
information contained in the database and register. Genetic research is, as per section 8, 
permitted for the purpose of studying and describing the mutual connection between 
genes, human state of health and physical and social environment in order to discover 
disease diagnostic and treatment methods that will help to assess the health risks of 
individuals and prevent the causes of diseases.  
 
As per the Human Genome Research Law (2003) the Cabinet shall publish regulations 
specifying the procedures for genetic research. All processing of information in the 
database shall be subject to the provisions for processing of personal data. Donors of 
genetic information must consent to the use of their information in a particular way and 
have the right to be informed of all the information produced as a result of processing of 
their genetic data. It is only permitted to use the genome database for scientific 
research, research and treatment of the diseases of a gene donor, research of the health 
of society and for statistical purposes. It is prohibited to use the genome database for 
any other purpose. The Law provides for how information is to be coded and de-identified 
during research. All research projects must comply with principles of ethics published by 
the Central Medical Ethics Committee which shall evaluate compliance with those 
principles in all projects relating to genetics research.  
 
                                                                                                                                    
101 – Ratification and implementation of the international resource treaty phytogenetics for food and 
agriculture, with appendices adopted by the thirty-first meeting of the FAO Conference in Rome on 3 
November 2001 
(133)  Sexual and Reproductive Health Law (2002)  
(134)  Human Genome Research Law (2003)  
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Patents 
The Patent Law (2007) is a standard patent legislation, which is essentially the same as 
the patent laws above and below (135). The Law as per section 10 prohibits human 
cloning, modification of the genetic identity of human beings and their germ line, 
utilisation of human embryos for industrial or commercial purposes and methods for 
modifying the genetic identity of animals likely to cause them suffering without any 
substantial medical benefit to people or animals. Furthermore, a human body in different 
stages of formation and development and a simple discovery of one of its elements, 
including the sequence or partial sequence of a gene, may not be a patented invention. 
An element which has been isolated from the human body or otherwise acquired with a 
technical method, including the sequence or a partial sequence of a gene, may not be a 
patented invention.  
 
Criminal context 
The Law on Development and Use of National DNA Database (2004) establishes a 
national DNA database to record criminal offences; the Law also regulates the exchange 
of the results of DNA genetic analysis with other States and international organisations 
(136). The Law prohibits discrimination against persons based on their genetic 
characteristics. The Law specifies when DNA can be collected from suspects, convict and 
other persons and when such profiles need to be destroyed.  
 
GMOs, Environmental and agricultural laws 
The Plant Varieties Protection Law (2002) provides for protection of plant varieties and 
describes the ways in which varieties may be protected (137). The Law on Circulation of 
Genetically Modified Organisms (2007) is largely a standard GMO legislation regulating 
the use of GMOs, their release and marketing (138). It gives the relevant Minister power 
to promulgate regulations with respect to GMOs which will contain the finer details of 
GMO rules on licencing. Interestingly, section 23 prohibits the release of deliberately 
genetically modified organisms containing genes, with code resistance to antibiotics used 
in medicine or veterinary uses, if it is determined in the risk assessment of potential 
effect of gene transfer of the particular genetically modified organism, that they have an 
adverse effect on human and animal health or the environment. 
 
3.18 Lithuania 
 
General Outline  
The Lithuanian laws on genomes are comprehensive and cover a wide variety of topics. 
The most significant legislation is the Law on Ethics in Biomedical Research (2002). This 
Law is the most comprehensive legislation on genome research and gene technology use 
in the surveyed jurisdictions. It sets out when embryos are allowed to be used, where 
human genomes can be modified and what principles are to be followed in any such 
research. Lithuanian laws on patents, animals, environment, GMOs as well as criminal 
procedure also cover genetics.  
 
Most relevant legislation: Law on Ethics in Biomedical Research (2002) 
                                           
(135)  Patent Law (2007)  
(136)  Law on Development and Use of the National DNA Database (2004)  
(137)  Plant Varieties Protection Law (2002) 
(138)  Law on Circulation of Genetically Modified Organisms (2007) 
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Patents 
The Patent Law (1994) is standard and extremely similar, nigh identical, to other patent 
statutes above and below in this document (139). As per Article 2 it prohibits patents for 
methods of human cloning, modification of the genetic identity of human beings and their 
germ line, utilisation of human embryos for industrial or commercial purposes and 
methods for modifying the genetic identity of animals likely to cause them suffering 
without any substantial medical benefit to people or animals, as well as animals resulting 
from such methods. 
 
Health laws and embryo research 
The Law on the Rights of Patients and Compensation for the Damage to Their Health 
(1996) prohibits discrimination or restriction of patient rights based on their genetic 
characteristics (140). The Law on Artificial Fertilisation (2014) prohibits the use of IVF as a 
means of modifying the identity of the germ line of a person or their offspring (141).  
 
The Law on Ethics in Biomedical Research (2002) provides in Article 3 that where human 
embryos or foetuses are used in biomedical studies (142), only those where the benefits 
are expected to outweigh the risks for the human embryo and human foetus are allowed. 
It is forbidden to use embryos that have died after a pregnancy termination when there 
are no medical indications. It is prohibited to carry out studies where the embryo or 
foetus is destroyed as a result of the study. The law provides further that human cloning 
is prohibited; and biomedical studies which modify the human genome may only be 
carried out for the purposes of prevention, diagnosis or treatment and only in cases 
where they are not intended to modify the progeny genome (the germ line).  
 
According to the Law on Ethics in Biomedical Research (2002), per Article 4, it is 
prohibited to discriminate against a person or restrict his or her rights or legitimate 
interest based on results of the genetic studies. Article 5 provides the ethical 
requirements for biomedical research which must be followed at all times. The Law 
specifies that consent is necessary for participation in research; and consent is also 
crucial for an individual’s information to be stored in a biobank. The Law regulates the 
establishment, running and obligations of biobanks as well as the protection of all genetic 
information.  
 
Criminal context  
The Police Law (2000) authorises relevant officials to take samples of genetic material 
without consent for comparative study and identification purposes (143). The Law on the 
Approval, Entry into Effect and Implementation of Criminal Procedure (2002) provides 
when suspects’ genetic information can be taken, despite the lack of consent of the 
suspect.  
 
GMOs, animal, environmental and agricultural laws 
                                           
(139)  Patent Law (1994)  
(140)  Law on the Rights of Patients and Compensation for the Damage to Their Health (1996)  
(141)  Law on Artificial Fertilisation (2014)  
(142)  Law on Ethics in Biomedical Research (2002)  
(143)  Police Law (2000) 
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The Law on Animal Welfare and Protection (1997) prohibits raising of genetically 
defective animals or pets with obvious genetic diseases, malformations or pathologies 
(144). It is also prohibited to exhibit genetically defective pets with the same defects.  
 
The Law on Advertising (2000) provides that food containing GMOs must be so labelled 
and  labelled in line with the latest regulations, issued under the authority of this Law 
(145). The Law on Genetically Modified Organisms (2001) is a standard GMO statute which 
sets up the regulatory regime for genetically modified organisms (146). The Law provides 
regulations on the contained use, deliberate release and marketing of GMOs and GMO 
products and specifies the licensing procedures, related safety measures and gives the 
Ministry of the Environment the authority to establish and manage a database of all 
GMOs and GMO products. The Law also contains offence and liability provisions for users 
who breach any provisions of the Law. The Environmental Protection State Controls Law 
(2002) provides that the state authorities shall control the limited use of GMOs and their 
release into the environment in accordance with the law (147). 
 
The Plant National Genetic Resources Law (2001) regulates plant genetic resources and 
stipulates those as the national resources of the Republic of Lithuania and an integral 
part of the State’s living resources (148.) The Act further specifies how seed and plant 
genetic material is to be stored, handled and conserved.  
 
Other 
The Insurance Law (2003) prohibits insurers taking any genetic data of the potential 
insured into their calculations in any way (149).  
 
3.19 Luxembourg 
 
General Outline 
The laws of Luxembourg on the genome are relatively comprehensive but no legislation 
could be located which covered embryo research or stem cell research.  It is possible that 
such regulation is contained in secondary or local regulations and hence outside of the 
scope of this review. The most significant legislation located is likely the Health Code 
which provides for regulations on gene therapy and genetic research.  
 
Most relevant legislation: Health Code 
 
Health laws 
The Health Code establishes an ethics committee with respect to gene therapy and 
genetic research as well as any related clinical trials (150). The Code specifies how 
sensitive data, including genetic data, are to be handled, stored and destroyed. The Code 
                                           
(144)  Law on Animal Welfare and Protection (1997)  
(145)  Law on Advertising (2000)  
(146)  Law on Genetically Modified Organisms (2001)  
(147)  Environmental Protection State Controls Law (2002) 
(148)  Plant National Genetic Resources Law (2001) 
(149)  Insurance Law (2003)  
(150)  Health Code  
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further provides for rules on the behaviour of inspectors whose duties include inspecting 
GMOs in medicines.  
 
Criminal context 
The Penal Code provides for the use of DNA in the context of criminal proceedings (151). 
It specifies when DNA samples can be collected from suspects or convicts and the exact 
procedure of doing so. It provides for the protection of all DNA data collected and how 
the samples are to be stored and handled. Law of 25 August 2006 on DNA identification 
procedures in criminal matters and the amending Code of Criminal procedure specifies 
some further details to the Penal Code.  
 
Patents 
The updated Law of 7 April Amending the Amended Law of 20 July 1992 Amending the 
Patent System, is typical of patent legislation, as seen in numerous legislations above 
(152).  
 
GMOs and agricultural laws 
The Law of 13 January 1997 on the Control of the Use and Dissemination of Genetically 
Modified Organisms is another standard GMO legislation which regulates the contained 
use, deliberate release and marketing of GMOs (153). The Law provides for procedures for 
licensing, safety measures and requirements as well as reporting obligations and 
associated liabilities and penalty provisions.  
 
The Law of 18 March 2008 on the marketing of seeds and seedlings and the coexistence 
of genetically modified, conventional and organic crops provides for how GMO crops and 
seeds can coexist and be marketed on the same market (154). Similarly, Law of 17 
November 2017 on the marketing of fruit plant propagating material and fruit plants 
intended for the production of fruit does so for genetically modified fruit and the Law 
specifies that any GMO fruit must be so labelled (155).  
 
Data protection  
The Law of 2 August 2002 on the Protection of Individuals with regard to the Processing 
of Personal Data provides for security protections of genetic data classified as health 
data, which is subject to higher protection than other kinds of data (156).  
 
Other 
The Law of 27 July 1997 on the Insurance Contract prohibits use of genetic information in 
the insurance context, as several laws in jurisdictions above have done (157). 
 
                                           
(151)  Penal Code  
(152)  Law of 7 April 2006 amending the amended Law of 20 July 1992 amending the patent system 
(153)  Law of 13 January 1997 on the control of the use and dissemination of genetically modified organisms 
(154)  Law of 18 March 2008 on the marketing of seeds and seedlings and the coexistence of genetically 
modified, conventional and organic crops  
(155)  Law of 17 November 2017 on the marketing of fruit plant propagating material and fruit plants 
intended for the production of fruit 
(156)  Law of 2 August 2002 on the protection of individuals with regard to the processing of personal data 
(157)  Law of 27 July 1997 on the insurance contract  
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3.20 Malta 
 
General Outline 
Laws of Malta on the genome are comprehensive and cover many topics, including 
environmental protection, GMOs, animal welfare, food safety, patents and genetic 
testing. The most significant legislation is the Embryo Protection Act (2013), which 
prohibits sex-selection of embryos and altering of the human germ line.   
 
Most relevant legislation: Embryo Protection Act (2013) 
 
Patents 
The Patents and Designs Act (2002) is another standard patent statute which (158), as 
per section 4, prohibits patents for methods of human cloning, modification of the genetic 
identity of human beings and their germ line, utilisation of human embryos for industrial 
or commercial purposes and methods for modifying the genetic identity of animals likely 
to cause them suffering without any substantial medical benefit to people or animals. It 
also specifies that Patents shall not be granted in respect of the human body including 
the sequence or partial sequence of a gene. An element isolated from the human body by 
means of a technical process, including the sequence of a gene, may constitute a 
patentable invention.  
 
Health laws and embryo research 
The Clinical Trials Regulations (2004) specify that the Ethics Committee must supervise 
and approve all clinical trials and may get an extension on its decision time if the drugs 
or therapies under consideration are gene therapies or contain genetically modified 
organisms (159).  
 
The Embryo Protection Act (2013) prohibits the selection of embryos based on the 
presence or absence of a sex-chromosome, except where it is done to prevent the 
occurrence of a sex-linked genetic illness (160). Section 11 of the Act prohibits any acts 
and interventions seeking to clone human beings. Section 13 specifies that it is a criminal 
offence punishable by imprisonment and a substantial fine to alter in an artificial way the 
genetic information of a human germ line; it is also an offence to knowingly use such a 
cell. It is not an offence if a medical practitioner does any of these acts as unintended 
consequences of inoculation, radiation or chemotherapeutic treatment. It is further an 
offence to unite embryos with different genetic material to a cell conglomerate using at 
least one human embryo. It is also an offence to join a human embryo with a cell that 
contains genetic information different from the embryo cells and induces them to develop 
further. 
 
Criminal context 
The Criminal Code (1854) specifies who can collect DNA in criminal proceedings and 
when DNA can be transmitted outside Malta (161).  
 
                                           
(158)  Patents and Designs Act (2002) 
(159)  Clinical Trials Regulations (2004) 
(160)  Embryo Protection Act (2013) 
(161)  Criminal Code (1854) 
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GMOs, animal and environmental laws 
The Animal Welfare Act (2002) specifies that only persons with a licence by the Minister 
(162), acting on the advice of the Council and the Director of Veterinary Services, may 
carry out the alteration of the genetic material of animals in a manner which ignores the 
natural barriers of sexual reproduction and recombination. The Environmental Protection 
Act (2016) specifies that the Minister may make regulations with respect to access to 
genetic resources (163).  
 
The Food Safety Act (2002) establishes the Food Safety Commission which has as one of 
its functions to regulate and oversee the safety of GMO foods (164). The Act also gives the 
Minister the power to make regulations with respect of GMO foods. The Contained Use of 
Genetically Modified Micro-Organisms Regulations (2008) and the Deliberate Release into 
the Environment of Genetically Modified Organisms Regulations (2010) are standard GMO 
legislative instruments which provide for the contained use, deliberate release and 
marketing of GMOs and GMO products (165). They also provide for the associated safety 
measures, licensing procedures and penalties.  
 
Other 
The Civil Code (1870) contains several provisions relating to the parentage of a child and 
disputes about paternity of a child including who is allowed to force a DNA sample to be 
given and what genetic samples can be used in this context (which is mainly to prove the 
relationship between persons) (166). The Work-Based Learning and Apprenticeship Act 
(2018) provides that the training programmes’ entry requirements and the selection of 
students shall be equitable and free from discrimination on the grounds of genetic 
features (167). 
 
3.21 The Netherlands 
 
General Outline 
Dutch laws relating to the genome are comprehensive and cover topics of DNA in the 
context of crime, environmental protection, GMOs, patents, animal laws and embryo 
research, as well as medical research on humans. The most significant pieces of 
legislation are likely the Law on Medical Research on Humans of 26 February 1998 and 
the Embryo Law of 20 June 2002, which directly relate to genetic research and the 
permitted uses of embryos in research.  
 
Most relevant legislation: Law on Medical Research on Humans of 26 February 1998 and 
the Embryo Law of 20 June 2002 
 
Health laws and embryo research  
                                           
(162)  Animal Welfare Act (2002)  
(163)  Environment Protection Act (2016)  
(164)  Food Safety Act (2002) 
(165)  Contained Use of Genetically Modified Micro-Organisms Regulations (2008); Deliberate Release into 
the Environment of Genetically Modified Organisms Regulations (2010)  
(166)  Civil Code (1870)  
(167)  Work-Based Learning and Apprenticeship Act (2018) 
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The Law on Medical Research on Humans of 26 February 1998 regulates medical 
research on humans (168).  It specifies how gene therapies are to be researched and it 
forbids experimentations on humans in a way that changes the germ line of humans. 
 
The Embryo Law of 20 June 2002 forbids all actions involving germ cells or embryos with 
a view to the birth of a genetically identical human being (169), or to deliberately modify 
the genetic material of the nucleus of human germ cells which might establish a 
pregnancy. 
 
Patents 
The Patent Act of 15 December 1994 is a standard patents statute which, according to 
Article 3 (170), prohibits patents for methods of human cloning, modification of the 
genetic identity of human beings and their germ line, utilisation of human embryos for 
industrial or commercial purposes and methods for modifying the genetic identity of 
animals likely to cause them suffering without any substantial medical benefit to people 
or animals, as well as animals resulting from such methods. 
 
Criminal context 
The Code of Criminal Procedure of 15 January 1921 provides for when DNA samples can 
be taken with and without consent from suspects (171) and specifies the collection 
procedure, handling and analysis of all DNA samples in the context of a criminal 
investigation and/or proceeding. Law on DNA and Convicted Persons of 16 September 
2004 provides further details on how DNA analysis is to be carried out in the context of a 
criminal proceeding and specifies when collections of DNA samples are allowed (172).  
 
GMOs, Environmental and animal laws 
Law on Animal Testing of 12 January 1977 provides when animal experiments end with 
regards to genetically modified animal lines (173). The Animal Law of 19 May 2011 forbids 
changing genetic material of animals solely for the purpose of enhancing their sporting 
performance or entertainment in a manner that ignores the natural barriers of sexual 
reproduction and recombination (174). It also prohibits the use of biotechnological 
techniques on animal or animal embryos without a permit. 
 
The Law on Environmental Conservation of 13 June 1979 establishes the Genetic 
Modification Committee (175), which advises the Minister on applications for 
authorisations for the use of GMOs. The Law provides how licences can be obtained for 
the contained use of GMOs, their deliberate release and marketing. It further specifies 
the relevant safety requirements and ongoing obligations of licensees. The Law also 
regulates the appropriate packaging and labelling of GMOs and GMO products. The Seed 
and Planting Materials Law of 19 February 2005 mandates that trading in seeds must be 
done with genetic diversity in mind (176), but exemptions for GMOs can be granted by the 
Minister. 
                                           
(168)  Law on Medical Research on Humans of 26 February 1998  
(169)  Embryo Law of 20 June 2002  
(170)  Patent Act of 15 December 1994  
(171)  Code of Criminal Procedure of 15 January 1921  
(172)  Law on DNA and Convicted Persons of 16 September 2004  
(173)  Law on Animal Testing of 12 January 1977  
(174)  Animal Law of 19 May 2011  
(175)  Law on Environmental Conservation of 13 June 1979  
(176)  Seed and Planting Materials Law of 19 February 2005 
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3.22 Norway 
 
General Outline  
Norwegian laws related to genetics are comprehensive and cover varied topics, including 
environmental protection, animal laws, patent as well as GMOs. The most crucial 
legislative instruments are the Act on Human Medicine Use of Biotechnology, etc. 
(Biotechnology Act) (2003) and the Law on Treatment Biobanks (Treatment Biobank Act) 
(2003) which regulate how research on embryos is performed and what genetic research 
is permitted. 
 
Most relevant legislation: The Act on Human Medicine Use of Biotechnology, etc. 
(Biotechnology Act) (2003) and the Law on Treatment Biobanks (Treatment Biobank Act) 
(2003) 
 
Health law and biotechnology  
The Act on Human Medicine Use of Biotechnology, etc. (Biotechnology Act) (2003) 
regulates when genetic studies and gene therapy courses can be implemented. It further 
prohibits genetic modification of frozen eggs which are later use in IVF (177). The law also 
regulates when fertilised eggs may be used for research; prohibits research that causes 
genetic changes which may be inherited in humans; and prohibits production of embryos 
by cloning. The Law also outlines the circumstances when genetic counselling or 
‘guidance’ should be given to the woman or couple expecting a child. The Act also 
provides when and how genetic analysis and/or studies can be conducted on individuals; 
and who is allowed access to genetic information.  
 
The Law on Treatment Biobanks (Treatment Biobank Act) (2003) provides what consent 
is necessary and under what circumstances may people access the information in a 
biobank (178). The Law also specifies the procedure via which information is deposited in 
a biobank.  
 
Patents  
The Patent Act (1967) appears to be the standard patent statute seen in many instances 
above and below in this report.(179) Sections 1, 1a, 1b and 3a prohibit patents for 
methods of human cloning, modification of the genetic identity of human beings and their 
germline, utilisation of human embryos for industrial or commercial purposes and 
methods for modifying the genetic identity of animals likely to cause them suffering 
without any substantial medical benefit to people or animals as well as animals resulting 
from such methods. 
 
GMOs, agricultural, environmental and animal laws 
The Law on the production and use of genetically modified organisms etc. (Genetic 
Technology Act) (1993) is a standard GMO statute which regulates the contained use, 
deliberate release and marketing of GMOs and GMO products (180). The Law provides for 
                                           
(177)  The Act on Human Medicine Use of Biotechnology, etc. (Biotechnology Act) (2003)  
(178)  Law on Treatment Biobanks (Treatment Biobank Act) (2003)  
(179)  Patent Act (1967)  
(180)  Law on the production and use of genetically modified organisms etc. (Genetic Technology Act) (1993) 
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safety measures, reporting obligations as well as availability of information to the public 
relating to GMOs.  
 
The Law on Animal Welfare (2009) prohibits breeding in animals using genetic 
engineering methods (181), and the Nature Conservation Act (Nature Diversity Act) 
(2009) outlines when species are designated as priority species (182), and it aims to 
protect the genetic diversity of animals and plants in the wild. The priority species are 
afforded special protection status.  
 
3.23 Poland 
 
General Outline 
The Polish laws relating to genetics cover several topics, but it must be noted that the 
website source has limited the ability of the author to locate more. The most relevant law 
is likely the Act of 22 June 2001 on Microorganisms and genetically modified organisms 
which regulates the use of genetically modified organisms.  
 
Most relevant legislation: Act of 22 June 2001 on Microorganisms and genetically 
modified organisms 
 
Patents 
The Act of 9 May 2007 about Amending the Act on Copyright and Related Rights and 
some other Laws (this is the Act’s name) (183) regulates copyrights and patents and is 
one of the biggest amendments in the past few decades in this area. There is no specific 
section covering genes, but the law may still be relevant.  
 
Health laws 
The Act of 1 July 2005 on the Collection, Storage and Transplantation of Cells, Tissues 
and Organs regulates collection, storage and transplantation of cells in humans (184). It 
sets up tissue banks where cells and tissues are to be stored; and details the procedures 
for confidentiality and safety that are to be followed. It also prohibits certain acts with 
respect to cells, tissues and organs. It is forbidden to pay for any cells, tissues and 
organs from donors.  
 
GMOs and environmental protection 
Act of 22 June 2001 on Microorganisms and genetically modified organisms is a standard 
piece of GMO legislation (185) which regulates the contained use, deliberate release and 
marketing of GMOs and GMO products. The Law provides for safety measures, reporting 
obligations as well as availability of public information relating to GMOs. The Act on Plant 
Protection provides for special powers of Inspector with respect to GMOs and inspections 
of crops.(186)  
                                           
(181)  Law on Animal Welfare (2009)  
(182)  Nature Conservation Act (Nature Diversity Act) (2009)  
(183)  Act of 9 May 2007 about Amending the Act on Copyright and Related Rights and some other Laws 
(184)  Act of 1 July 2005 on the Collection, Storage and Transplantation of Cells, Tissues and Organs 
(185)  Act of 22 June 2001 on Microorganisms and genetically modified organisms 
(186)  Act on Plant Protection  
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3.24 Portugal 
 
General Outline 
The Portuguese laws relating to genetics are comprehensive and cover many topics. The 
most relevant and notable law is Law no 12/2015 of 26 January on Personal Genetic 
Information and Health Information, which provides an in-depth regulation of genetic 
research, storage of genetic information as well as the limits of procedures which can be 
utilised in working with genetic information. This appears to be one of the most 
comprehensive pieces of legislation focusing on genetics among the EU jurisdictions. 
 
Most relevant legislation: Law no 12/2015 of 26 January on Personal Genetic Information 
and Health Information 
 
Health laws and genetic research 
The Law no 12/2015 of 26 January on Personal Genetic Information and Health 
Information creates a comprehensive regulatory framework for genetic research, storage 
of genetic information as well as the limits of procedures relating to genetic information 
(187). The Law protects the privacy of genetic information and places special protections 
on the data; for example, it dictates that genetic and health information be treated 
separately and only persons with the highest levels of access can have access. The Law 
prohibits the alteration of the human germ line and outlines what a genetic database is 
and what permissions must be obtained before setting such a database up. The Act has a 
chapter on genetic testing whereby it limits the availability of testing and provides that 
informed consent of the patient must be obtained prior to testing. The Law also prohibits 
discrimination of any person on the basis of their genetic information or the fact that they 
have a certain genetic disease. Similarly, insurance companies cannot request access to 
any genetic information nor can they use such information in setting the insurance 
premiums. Further, genetic testing in employment is prohibited and cannot be used for 
recruitment purposes, unless there is some risk to a person with special susceptibility.  
 
Human genome research is to follow the general rules on scientific research in the field of 
health, with additional confidentiality protections. Free access by the scientific community 
to emerging data on the human genome must be guaranteed. Research on the human 
genome is subject to approval by the ethics committees of the relevant hospital, 
university or research institution. Such research cannot be carried out without the 
informed consent of the subject. The law also regulates the set-up of DNA banks and 
tissue banks.  
 
The Law no 32/2006 of 26 July on Medically Assisted Procreation regulates all matters 
related to IVF and embryo research including the limits on genetic manipulation (188). It 
is thereby prohibited to create a human being genetically identical to another human. It 
is forbidden to sex-select embryos other than for the purpose of preventing a serious 
sex-linked genetic disease. It is forbidden to use pre-implantation genetic diagnosis for 
multifactorial diseases where the predictive value of the test is very low. Use of embryos 
in research is only allowed when the research is expected to be of great benefit to 
humanity. There are limits on what embryos are allowed to be used for research; one 
                                           
(187)  Law no 12/2015 of 26 January on Personal Genetic Information and Health Information 
(188)  Law no 32/2006 of 26 July on Medically Assisted Procreation  
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source of embryos is embryos which have been identified in pre-implantation genetic 
diagnosis as having a severe genetic abnormality. The Law also provides for when pre-
implantation genetic diagnosis can be performed.  
 
Criminal context 
The Law no 5/2008 of 12 February on the DNA Profile Database – Civil and Criminal 
Identification regulates and establishes DNA profile database for both criminal and civil 
litigation (189). It regulates how the DNA data is to be stored and handled and what 
safety measures must be in place and for what purposes can DNA be collected.  
 
Patents 
The Industrial Property Code – Law no 36/2003 of 5 March is a standard patent statute, 
as seen in the majority of the jurisdictions included in this report. Article 53 prohibits 
patents for methods of human cloning, modification of the genetic identity of human 
beings and their germ line, utilisation of human embryos for industrial or commercial 
purposes and methods for modifying the genetic identity of animals likely to cause them 
suffering without any substantial medical benefit to people or animals as well as animals 
resulting from such methods. Article 54 provides that the following can be patented, a 
novel invention which involves an inventive step and is capable of industrial application 
affecting any element isolated from the human body or otherwise produced by a 
technical process, including the sequence or partial sequence of a gene.  The structure of 
that element is identical to that of a natural element, provided that the industrial 
application of a sequence or a partial sequence of a gene is observed and concretely 
disclosed in the patent application. 
 
Data protection  
The Law no 67/1998 of 26 October on Personal Data Protection Act regulates access to 
and handling of personal data (190); the personal data includes genetic information. 
Genetic information is classified as sensitive personal information and special procedures 
must be employed when handling such data. Law no 94/1999 of 16 July on Access to 
Documents regulates access to official documents and it specifies how documents 
containing genetic information can be accessed (191). 
 
GMOs and environmental laws 
The Law no 142/2008 of 24 July for the Conservation of Nature and Biodiversity outlines 
measures to maintain and protect biodiversity of the environment (192). 
 
The Law no 55/2015 of 17 April on the Confined Use of Genetically Modified 
Microorganisms and Organisms regulates GMOs and their contained use (193). It covers 
the permits, procedures and processes to be employed in connection to GMOs. It is yet 
another instance of the standard GMO statute.  
 
                                           
(189)  Law no 5/2008 of 12 February on the DNA Profile Database – Civil and Criminal Identification 
(190)  Law no 67/1998 of 26 October on Personal Data Protection Act  
(191)  Law no 94/1999 of 16 July on Access to Documents  
(192)  Law no 142/2008 of 24 July for the Conservation of Nature and Biodiversity 
(193)  Law no 55/2015 of 17 April on the Confined Use of Genetically Modified Microorganisms and Organisms 
 63 
3.25 Romania 
 
General Outline 
The Romanian laws on genetics are comprehensive and cover topics ranging from DNA 
databases in criminal procedure, GMOs, animal laws and extensive laws on embryo 
research as well as the permitted biotechnological techniques. 
 
Most relevant legislation: Civil Code of 17 July 2009 (Law 287/2009) 
 
Health law and embryo research 
Civil Code of 17 July 2009 (Law 287/2009) prohibits any medical intervention intended to 
modify the genetic information of offspring of an individual (194), except for the purpose 
of preventing and/or treating genetic diseases. It further prohibits the creation of 
genetically identical humans even if one is deceased and prohibits the choosing of the 
sex of an embryo unless the reason for the choice is to avoid or prevent a genetic 
disease. The Code further provides that genetic examination can only be undertaken for 
medical or scientific purposes and must be permitted by law. The identification of a 
person on the basis of his/her genetic profile may be done only in the course of a civil or 
criminal judicial procedure or for medical or scientific research (permitted by law).  
 
The Law no. 2 of 8 January 1998 on the procurement and transplantation of human 
tissues and organs governs when and how transplants are allowed (195). The donor must 
be genetically compatible with the recipient of the tissue or organ.  
 
Criminal context 
The Code of Criminal procedure of 1 July 2010 (Law 135/2010) outlines when genetic 
samples can be taken in the context of criminal proceedings and/or investigation (196). 
The Law no. 76 of 8 April 2008 on the organisation and operation of the National System 
of Judicial Genetic Data establishes the National System of Judicial Genetic Data and sets 
out the conditions under which DNA samples can be taken from suspects and convicts; 
and how the data is to be processed and stored (197). 
 
Animal laws 
The Law no. 362 of 10 July 2001 for the approval of the Government Emergency 
Ordinance no. 33/2000 on the financing from the state budget of measures for the 
protection of the genetic patrimony of animals establishes the legal framework for 
financing the maintenance and preservation of genetic information of animals.(198) The 
Law no. 43 of 11 April 2014 on the protection of animals used for scientific purposes 
defines ‘procedure’ as excluding actions leading to the creation or maintenance of a line 
of genetically modified animals (199). This means that the permitted ‘procedures’ do not 
include, and thereby prohibit, such procedures which would lead to the creation or 
maintenance of genetically modified animals.  
                                           
(194)  Civil Code of 17 July 2009 (Law 287/2009)  
(195)  Law no. 2 of 8 January 1998 on the procurement and transplantation of human tissues and organs 
(196)  Code of Criminal procedure of 1 July 2010 (Law 135/2010) 
(197)  Law no. 76 of 8 April 2008 on the organisation and operation of the National System of Judicial Genetic 
Data 
(198)  Law no. 362 of 10 July 2001 for the approval of the Government Emergency Ordinance no. 33/2000 on 
the financing from the state budget of measures for the protection of the genetic patrimony of animals 
(199)  Law no. 43 of 11 April 2014 on the protection of animals used for scientific purposes  
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The Law no. 72 of 16 January 2002 on biological techniques provides that embryo 
transfer biotechnologies and experimental genetic manipulation are allowed to be used in 
institutes of scientific research and higher education (200), but need to be carried out 
under the control of the Ministry of Agriculture and Rural Development. The law regulates 
the import and export of animals’ genetic resources and specifies that the genetic 
improvement of animals should be carried out by selective breeding and hybridisation.  
 
GMOs 
Law no. 214 of 19 April 2002 for the approval of the Government Ordinance no. 49/2000 
on the regime for obtaining, testing, use and commercialisation of genetically modified 
organisms through the modern biotechnology techniques, as well as the products 
resulting therefrom regulates the production, testing, use and commercialisation of 
genetically modified organism and outlines the regulations especially with respect to 
contained and uncontained use of genetically modified organisms (201). Together with 
Law no. 3 of 9 January 2008 for the approval of Government Emergency Ordinance no. 
44/2007 on the contained use of genetically modified micro-organisms and the Law no. 
247 of 30 June 2009 for the approval of Government Emergency Ordinance no. 43/2007 
on the deliberate introduction into the environment and on the placing on the market of 
genetically modified organisms, these statutes appear to be a standard GMO legislation 
(202). They cover the permits, procedures and processes to be employed in connection to 
GMOs. 
 
3.26 Slovakia 
 
General Outline 
There does not appear to be specific legislation on gene technologies and/or research. 
The Slovakian legislation which relates to genetics covers abortion, environmental 
protection, animal welfare, patents, GMOs, criminal offences and data protection.  
 
Most relevant legislation: Patent Law 435/2001 
 
Health laws 
Law on abortion 73/1986 permits an abortion where there is a genetic abnormality in the 
foetus. 
 
Patents 
The Patent Law 435/2001 is a standard patents legislation and section 6 prohibits patents 
for methods of human cloning (203), modification of the genetic identity of human beings 
and their germ line, utilisation of human embryos for industrial or commercial purposes 
                                           
(200)  Law no. 72 of 16 January 2002 on biological techniques  
(201)  Law no. 214 of 19 April 2002 for the approval of the Government Ordinance no. 49/2000 on the 
regime for obtaining, testing, use and commercialisation of genetically modified organisms through the 
modern biotechnology techniques, as well as the products resulting therefrom  
(202)  Law no. 3 of 9 January 2008 for the approval of Government Emergency Ordinance no. 44/2007 on 
the contained use of genetically modified micro-organisms; Law no. 247 of 30 June 2009 for the 
approval of Government Emergency Ordinance no. 43/2007 on the deliberate introduction into the 
environment and on the placing on the market of genetically modified organisms  
(203)  Patent Law 435/2001  
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and methods for modifying the genetic identity of animals likely to cause them suffering 
without any substantial medical benefit to people or animals, as well as animals resulting 
from such methods. 
 
Data protection 
Law on the protection of personal data 18/2018 includes genetic information in personal 
data and genetic data is thus afforded a higher level of protection; and persons must give 
their consent for their genetic information to be processed, as per section 16 (204).  
 
GMOs, environmental, animal and agricultural laws 
The Law on the protection of plant genetic resources for agriculture 215/2001 aims to 
protect the genetic resources of plants for agriculture (205). The Law specifies that all 
genetic resources of plants in the territory of Slovakia are the natural heritage of the 
Republic. The law sets up storage facilities for the genetic resources of seeds and plants 
which are deemed important for agriculture and the safety of the foods supply. Law on 
protection of nature 543/2002 specifies as one of the factors for consideration when 
deciding which species are endangered, is genetic variability (206). The Law against 
animal abuse 246/1992 provides that experiments on animals are to be carried out on 
animals which are designated for that purpose and suited from a genetic perspective 
(207). 
 
The Law on Genetically Modified Organisms and Genetic Technologies 151/2002 is a 
standard GMO statute which regulates the contained use, deliberate release and 
marketing of GMOs and GMO products (208). The Law provides for safety measures, 
reporting obligations as well as availability of public information relating to GMOs. 
 
Criminal context  
Criminal Law 300/2005 prohibits the creation of a genetically identical human being to 
another one alive or dead. It is also an offence to breach the laws relating to GMOs and 
genetic technologies (209). 
 
Other 
Workplace law 311/2001 provides that all persons have the right to work and seek 
employment and shall not be discriminated against based on their characteristics such as 
their race, sexuality and genetic information (210). Similarly, it is forbidden to 
discriminate against people in the workplace on the basis of their genetics. 
 
3.27 Slovenia 
 
General Outline 
                                           
(204)  Law on the protection of personal data 18/2018  
(205)  Law on the protection of plant genetic resources for agriculture 215/2001  
(206)  Law on protection of nature 543/2002 
(207)  Law against animal abuse 246/1992  
(208)  Law on Genetically Modified Organisms and Genetic Technologies 151/2002  
(209)  Criminal Law 300/2005  
(210)  Workplace law 311/2001  
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Slovenian law relating to genetics covers several topics such as environmental protection, 
but does not appear to have a dedicated legislative instrument for genetic technologies, 
embryo research and/or biobanks.  
 
Most relevant legislation: Medicines Laws (2014) and Act on the Management of 
Genetically Modified Organisms (2002) 
 
Criminal context  
Law on Police Orders and Authorisations (2013) provides limits on police powers (211). It 
stipulates a principle of equal treatment prohibiting police offices to discriminate against 
anyone on the grounds of genetic heritage (Art. 14). 
 
Health laws 
Medicines Law (2014) regulates medicines and clinical trials (212). It specifies that no 
clinical trials can be conducted where the drug/treatment would change the germ line of 
the patient. It also provides for special authorisations necessary if a drug trial concerns a 
gene therapy treatment. The Act on Acquisition and Transplantation of Human Body Parts 
(2015) regulates transplantations (213). 
 
GMOs, environmental, animal and agricultural laws 
The Nature Conservation Act (1999) regulates conservation of nature and it specifies 
biodiversity as a measure of genetic diversity in populations of animals and plants in the 
wild (214). It enumerates measures to maintain and promote such diversity. The Law on 
Agriculture (2008) regulates agriculture and contains provisions intended to secure 
genetic diversity of crops and the like (215). 
 
The Law on Animal Husbandry (2002) regulates the breeding of animals and also covers 
aspects of experimentation on animals (216). It specifies which genetic modifications are 
permissible and which are not. It also emphasises that one of the purposes of the law is 
to maintain genetic diversity in animals, especially in livestock. 
 
The Act on the Management of Genetically Modified Organisms (2002) covers GMOs, 
their use in food, feed as well as the required safety procedures and permits for placing 
any GMO products on the market or releasing them into the environment (217). It appears 
to be a standard GMO legislation, which is very similar to the other GMO legislations in 
this report.  
 
3.28 Spain 
 
General Outline 
                                           
(211)  Law on Police Orders and Authorisations (2013)  
(212)  Medicines Law (2014) 
(213)  Transplantation of Human Body Parts (2015)  
(214)  Nature Conservation Act (1999)  
(215)  Law on Agriculture (2008) 
(216)  Law on Animal Husbandry (2002)  
(217)  The Act on the Management of Genetically Modified Organisms (2002)  
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Spanish laws relating to genetics cover a wide array of topics, but the most significant 
legislative instrument is the Health Code.  The Code incorporates a large number of 
individual laws, including the law on Biobanks and the law on Biomedical Research.  
 
Most relevant legislation: Health Code and a selection of the individual enactment 
thereby contained 
 
Criminal context 
The Penal Code and complementary legislation provides for when DNA samples can be 
taken for suspects and convicts; and outlines the procedures for collecting, storing and 
destroying DNA (218). The Code creates several offences relating to genetic information 
modification. Genetic modification in humans is prohibited for all purposes, except for 
those where the aim is to eliminate or reduce defect or serious disease. Breach of this 
provision carries a prison sentence. As per section 160, the use of genetic engineering to 
produce biological weapons is prohibited and punishable by imprisonment. It is prohibited 
to fertilise human eggs for any other purpose than for human reproduction; this provision 
carries a custodial sentence. The creation of genetically-identical humans (clones) is 
prohibited and will be punished by imprisonment.  
 
Health laws 
The Health Code specifies when genetic counselling is to be provided to individuals; and 
mandates that personal data, including genetic data, and the identity of donors of organs 
must remain secret (219). The Code also contains laws 9/2003 and 178/2004 on the Use 
of Genetically Modified organisms which are the standard GMO legislation that regulate 
the contained use, deliberate release and marketing of GMOs and GMO products (220). 
The Law provides for safety measures, reporting obligations as well as availability of 
public information relating to GMOs. 
 
The Code further incorporates the Law 14/2006 of 26 May on Assisted Reproduction, 
which includes very serious penalties including those for sex selection or genetic 
manipulation for non-therapeutic or non-authorised therapeutic purposes (221). Another 
very serious penalty is attached to the production of interspecific hybrids that use human 
genetic material, except in cases of permitted scientific research 
 
The Code also and importantly includes the Law 14/2007 of 3 July on Biomedical 
Research whereby one of the purposes of the law is to regulate the procedures of genetic 
analysis and the storage and handling of genetic data (222). It is prohibited to 
discriminate against any person because of their genetic characteristics, or due to their 
refusal to undergo a genetic analysis or to participate in genetic research. The law 
specifies what information must be provided to subjects and what consent must be 
acquired by the scientist.  
 
                                           
(218)  Penal Code and complementary legislation  
(219)  Health Code  
(220)  Law 9/2003 Use of Genetically Modified Organisms; Royal Decree 178/2004 – Regulations under the 
Law on the Use of Genetically Modified Organisms  
(221)  Law 14/2006 of 26 May on Assisted Reproduction  
(222)  Law 14/2007 of 3 July on Biomedical Research  
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The Code includes a Royal Decree 1716/2011 of 18 November on Biobanks, biological 
samples and the National Registry of Biobanks, which specifies that consent is needed to 
store, use or access any biological information in the biobank (223).  
 
Patents 
Law 10/2002 of 29 April which modifies Law 11/1986 on patents for the incorporation 
into Spanish Law of Directive 98/44 EX, of the European Parliament and of the Council of 
6 July concerning the legal protection of biotechnological inventions (224). This Law 
appears to be standard patent statute as seen in many places in this report.  
 
Environmental laws 
The Law 42/2007 of 13 December on Natural Heritage and Biodiversity establishes the 
Spanish Inventory Bank of Genetic Material and provides for the procedures of collecting 
the materials, storage, access and sharing of genetic materials with other nations (225).  
 
3.29 Sweden 
 
General Outline  
Swedish legislation provides two statutes which are directly relevant to genetic research, 
namely the Act on Biobanks in Healthcare, etc. 2002:297 and the Act on Genetic 
Integrity etc. 2006:351.  They outline the details on when embryonic research can be 
performed and what the limits of genetic research and gene therapy applications are and 
provide an example of one of the most thorough legislations on this topic. A notable 
detail is the limit on embryonic research 14 days post-fertilisation and a limit of up to 5 
years of freezing eggs; this is similar to the UK legislation and the Portuguese provisions.  
 
Most relevant legislation: Act on Biobanks in Healthcare, etc. 2002:297 and Act on 
Genetic Integrity etc. 2006:351  
 
Patents 
Patent Act 1967 is a standard patents statute, with the addition of prohibiting inventions 
which are against good practice and morality to be patented (226). Section 1 prohibits 
patents for methods of human cloning, modification of the genetic identity of human 
beings and their germ line, utilisation of human embryos for industrial or commercial 
purposes and methods for modifying the genetic identity of animals likely to cause them 
suffering without any substantial medical benefit to people or animals, as well as animals 
resulting from such methods. 
 
Health laws and genetic research  
                                           
(223)  Royal Decree 1716/2011 of 18 November on Biobanks, biological samples and National registry of 
Biobanks 
(224)  Law 10/2002 of 29 April which modifies Law 11/1986 on patents for the incorporation into Spanish 
Law of Directive 98/44 EX, of the European Parliament and of the Council of 6 July concerning the legal 
protection of biotechnological inventions  
(225)  Law 42/2007 of 13 December on Natural Heritage and Biodiversity 
(226)  Patent Act 1967:837  
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The Act on Biobanks in Healthcare, etc. 2002:297 does not explicitly refer to genes but 
its topic is closely related and storage of tissues for research can have implications for 
genetic studies (227.) The Act on Genetic Integrity etc. 2006:351 is the major legislation 
in Sweden relating to genetics (228). The Act prohibits insurance companies to require or 
request genetic information from the insured. Sections 3 and 4 (chapter 2) prohibit 
genetic research, experiments and treatment methods which could lead to genetic 
changes that could be inherited. The Act also outlines the requirements for the analyses 
of genetic information in the context of delivering health services or performing scientific 
research, as well as the conditions in which foetal genetic testing can be done.  It 
provides that research on embryos can be performed if the ethics committee approves 
the project and the embryo can be used for up to 14 days post fertilisation and limits the 
time of freezing of eggs/embryos to 5 years. The Act provides details on when IVF is 
allowed when the woman is not cohabiting with the sperm donor. The Act also provides 
when gene therapies can be used; and lists penalties for breaching any of the provisions 
of the Act.  
 
The Pharmaceuticals Act 2015:315 outlines how permissions for clinical trials are granted 
and provides extended decision periods for cases where the applicant wishes to use a 
gene therapy drug (229).  
 
 
GMOs, animal and environmental laws 
Animal Welfare Act 1988:588 limits when animals may be experimented on and when 
they can be subject to genetic modification (230). The Environmental bar (Code) regulates 
the use of GMOs (231). The statute appears to be fairly standard GMO law similar to many 
seen above. The Law regulates the contained use, deliberate release and marketing of 
GMOs and GMO products. The Law provides for safety measures, reporting obligations as 
well as availability of public information relating to GMOs. 
 
3.30 Switzerland 
 
General Outline  
Swiss laws relating to genetics are extremely comprehensive and cover the whole variety 
of topics which were encountered throughout the review. The Federal Act on Research 
Involving Embryonic Stem Cells (2003) and Federal Act on Human Genetic Testing 
(2004) and the Federal Act on Research Involving Human Beings (2011) provide a 
detailed framework on conducting research on humans, embryos and performing genetic 
testing. Interestingly, the Swiss constitution itself provides prohibition on cloning and 
interfering with embryonic cells, which means any significant changes to Swiss laws 
regarding these topics would require constitutional amendments.  
 
Most relevant legislation: Federal Act on Research Involving Embryonic Stem Cells 
(2003) and Federal Act on Human Genetic Testing (2004) and the Federal Act on 
Research Involving Human Beings (2011) 
 
                                           
(227)  Act on Biobanks in Healthcare, etc. 2002:297 
(228)  Act on Genetic Integrity etc. 2006:351  
(229)  Pharmaceuticals Act 2015:315 
(230)  Animal Welfare Act 1988:588  
(231)  Environmental bar (Code)  
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Health law, genetic testing and embryo research  
Article 119 of the Federal Constitution of the Swiss Federation gives people the right to 
be protected against the misuse of reproductive medicine and gene technology (232). The 
Confederation shall legislate on the use of human reproductive and genetic material. In 
doing so, it shall ensure the protection of human dignity, privacy and the family and shall 
adhere in particular to the following principles – all forms of cloning and interference with 
the genetic material of human reproductive cells and embryos is unlawful; non-human 
reproductive and genetic material may neither be introduced into nor combined with 
human reproductive material; IVF may only be used if there is an infertility issue or a risk 
of transmitting a serious illness and donation of embryos is unlawful.  
 
The Federal Act on Medically Assisted Reproduction (1998) regulates IVF (233). It also 
restricts analysis of genetic material of reproductive cells and embryos in vitro is to cases 
where selection of sex or other characteristics is necessary because of a risk that the 
presence of certain genes will inhibit the developmental capacity of the embryo and when 
there is no other way of avoiding a serious disease. Genetic counselling must be provided 
in all cases of genetic analysis of embryos. The Act also regulates how and when 
reproductive cells can be preserved, namely with the consent of the donor and for a 
maximum of 5 years and limits the number of embryos developed in the IVF context per 
woman to a maximum number of twelve. The Act creates an offence for acts whereby a 
person who in the course of a reproductive technique analyses the genetic material of 
reproductive cells or embryos in vitro and selects them according to their sex or 
according to other characteristics, without aiming to overcome infertility or avoid the 
transmission of the predisposition to a serious disease to the offspring shall be liable to a 
custodial sentence not exceeding three years or to a monetary penalty. 
 
The Federal Act on Research Involving Embryonic Stem Cells (2003) prohibits a number 
of acts including the creation of an embryo for research purposes (234), the modification 
of the genetic material in a germ cell, the derivation of embryonic stem cells from an 
embryo that has undergone germ line modification, or the use of such cells; it is also 
prohibited to create a clone, chimer or a hybrid. The Act creates serious criminal offences 
for breaches of any of the prohibited acts listed above.  
 
The Federal Act on Human Genetic Testing (2004) stipulates the conditions under which 
human genetic testing may be performed in the medical, employment, insurance and 
liability contexts (235). An overriding principle is given in Article 4, whereby no one can be 
discriminated against on grounds of their genetic characteristics. All genetic testing is to 
be performed only with the consent of the subject of the test. Genetic tests may only be 
performed on individuals if they serve a medical purpose and it is forbidden to perform 
prenatal tests for the purpose of:  
- determining the characteristics of the embryo or foetus which do not directly impair its 
health;  
or 
- determining the sex of the embryo or foetus for a purpose other than diagnostic.  
The Act further outlines extensive privacy and data protection relating to genetic 
information and any results from genetic processing. The Act prohibits the use of genetic 
information in the context of insurance and employment. An employer may request an 
                                           
(232)  Federal Constitution of the Swiss Federation  
(233)  Federal Act on Medically Assisted Reproduction (1998)  
(234)  Federal Act on Research Involving Embryonic Stem Cells (2003)  
(235)  Federal Act on Human Genetic Testing (2004)  
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employee take a genetic test for pre-symptomatic genetic diseases to prevent 
occupational diseases and accidents, this exception is narrow and highly regulated.  
 
The Federal Act on Research Involving Human Beings (2011) provides that biological 
material and genetic data in an un-coded form may be used for research projects if the 
subject has given informed consent for its use (236). The Act also outlines when data can 
be anonymised.  
 
Patents 
Federal Act on Patents for Inventions (1954) seems to be reasonably similar to other 
patent legislation above but contains more detail (237). Article 2 of the Act prohibits 
patents for processes for cloning human beings; processes for forming hybrid organisms 
by using human germ cells, human totipotent cells or human embryonic stem cells and 
the entities obtained thereby; processes of parthenogenesis by using human germinal 
material and the parthenogenetic entities obtained thereby; processes for modifying the 
germ line genetic identity of human beings and the germ line cells obtained thereby; 
unmodified human embryonic stem cells and stem cell lines; the use of human embryos 
for non-medical purposes and processes for modifying the genetic identity of animals 
which are likely to cause them suffering without being justified by overriding interests 
worthy of protection. 
 
The Federal Act on the Promotion of Research and Innovation (2012) does not specifically 
refer to genetics (238), but it is a statute to incentivise and support research in general, 
presumably including genetic research and applications of such research. It may 
therefore be relevant. 
 
GMOs and environmental laws 
The Federal Act on the Protection of Nature and Cultural Heritage (1966) outlines 
provisions on sharing genetic resources and incorporates the Nagoya Protocol 
(concerning sharing of genetic resources internationally) into Swiss law (239). 
 
The Federal Act on Non-human Gene Technology (2003) governs the area of GMOs and is 
fairly similar to the standard GMO legislation which was described many times above 
(240). The Act also establishes the Federal Ethics Committee on non-human 
biotechnology, which advises on ethical implications of use of GMOs and their handling.  
 
Criminal context 
The Swiss Criminal Code stipulates significant sanctions for causing danger in some way 
using GMOs and foreign nationals shall be expelled by court order if they are convicted of 
wilfully causing danger by means of GMOs, which  is an offence in any case (241). 
 
                                           
(236)  Federal Act on Research Involving Human Beings (2011)  
(237)  Federal Act on Patents for Inventions (1954)  
(238)  Federal Act on the Promotion of Research and Innovation (2012) 
(239)  Federal Act on the Protection of Nature and Cultural Heritage (1966)  
(240)  Federal Act on Non-human Gene Technology (2003)  
(241)  Swiss Criminal Code  
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3.31 United Kingdom 
 
General Outline  
The laws of the United Kingdom relating to genetics cover a wide variety of topics 
ranging from genetics in the criminal context to embryo research and patents. The most 
significant instruments are Human Tissue Act 2004 and the Human Fertilisation and 
Embryology Act 1990, with the latter establishing the Human Fertilisation and 
Embryology Authority which is a body that grants licences to researchers to perform 
embryonic and related genetic research, thus acting as the main regulator for what 
research is, and is not, carried out. There has been at least one instance in which a UK 
research team genetically edited human embryos, which reflects the Authority’s 
willingness to consider such actions for research purposes. See an Article with further 
detail here. 
 
Most relevant legislation: Human Tissue Act 2004 and the Human Fertilisation and 
Embryology Act 1990 
 
Health laws and embryo research 
The Abortion Act 1967 specifies when abortion is allowed, including if there is a 
substantial risk that if the child were born it would suffer from such physical or mental 
abnormalities as to be seriously handicapped (242). 
 
The Human Fertilisation and Embryology Act 1990 is the key legislation in embryo 
research in the UK (243). The Act establishes the Human Fertilisation and Embryology 
Authority that approves and licences research projects which use human tissue. The Act 
prohibits a number of acts including the creation of an embryo, except when holding a 
licence issued by the Authority. Generally speaking, without authorisation, there cannot 
be any genetic alterations of eggs and sperm and no person shall use modified germ cells 
to provide fertility services. The Act also provides for prohibitions in connection to genetic 
material of non-human origin, namely that:  
(1) no person shall place in a woman a human admixed embryo, other embryo that is not 
a human embryo or gametes that are not human gametes;  
(2) no person shall mix human gametes with animal gametes, bring about the creation of 
a human admixed embryo or keep or use such an embryo;   
(3) licences cannot authorise the keeping or using of a human admixed embryo after the 
appearance of the primitive streak or the end of 14 days beginning with the day on which 
the process of creating the embryo began, and  
(4) licences cannot authorise placing human admixed embryos in an animal or keeping or 
using a human admixed embryo in any circumstances in which regulations prohibit it. 
Hence there is a hard limit of 14 days for embryonic research from the time of 
fertilisation. The Act further provides details as to the licence procedure and application, 
as well as IVF itself.  
 
The Human Tissue Act 2004 does not strictly speaking relate to genetics (244), but it can 
have relevance in research and development of genetic techniques since it governs the 
                                           
(242)  Abortion (Foetus Protection) Bill 2017-19  
(243)  Human Fertilisation and Embryology Act 1990  
(244)  Human Tissue Act 2004  
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handling of human tissues, their collection as well as the required consents and 
permissions related to those activities.  
 
Patents 
The Patents Act 1977 is a standard patent statute, which is essentially identical to most 
of the patents statutes in the jurisdictions outlined above (245). It prohibits the 
patentability of processes for cloning human beings; processes for modifying the germ 
line genetic identity of human beings; uses of human embryos for industrial or 
commercial purposes; processes for modifying the genetic identity of animals which are 
likely to cause them suffering without any substantial medical benefit to man or animal. 
 
Criminal context 
The Police and Criminal Evidence Act 1984 regulates when DNA profiles can be included 
on the National DNA Database in the context of criminal investigations and/or 
proceedings.(246) The Act specifies when DNA samples and profiles can be destroyed and 
provides that the National DNA Database Strategy Board must make arrangements for 
the database operations. It is worth noting that the database had a controversial 
indefinite retention policy, but the Protection of Freedoms Act 2012 overturned the 
indefinite retention policy of the DNA database (247) in response to the European Court of 
Human Rights ruling in S. and Marper versus United Kingdom (ECHR 1581 - Applications 
n. 30562/04 and 30566/04). The Protection of Freedoms Act 2012 mainly regulates the 
use of DNA by the state and is designed to ensure freedoms of citizens and non-citizens 
to their genetic information.  
 
GMOs, environmental and food laws 
The Environmental Protection Act 1990 is the parent Act under which regulations relating 
to GMOs are promulgated (248). The relevant regulations are (1) The Genetically Modified 
Organisms (Risk Assessment) (Records and Exemptions) Regulations 1996 and (2) The 
Genetically Modified Organisms (Deliberate Release and Risk Assessment-Amendment) 
Regulations 1997. The Act provides for general provisions relating to GMO safety and risk 
assessment, but it is the regulations that contain the detail similar to other GMO statutes 
mentioned in previous jurisdictions.  
 
The Food Safety Act 1990 provides that the Secretary of State may make regulations 
with respect to genetically modified foods and GMO foods (foods where their source has 
been modified by an artificial technique or is derived from genetic material which was so 
modified) (249).  
 
Data protection 
The Data Protection Act 2018 regulates the protection of personal data, which includes 
genetic information (250). The Act provides more stringent protections to sensitive 
processing, which includes the processing of genetic data. The Act also limits the 
processing of genetic data by insurance providers. 
 
                                           
(245)  Patents Act 1977  
(246)  Police and Criminal Evidence Act 1984  
(247)  Protection of Freedoms Act 2012  
(248)  Environmental Protection Act 1990 
(249)  Food Safety Act 1990  
(250)  Data Protection Act 2018  
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4 Conclusions 
 
The present report shows that a large body of law exists in the member states of the 
European Union regarding the implementation of genomics technologies, both 
supervising the proper handling of the information produced (patents, personal data 
protection, DNA profiles in forensics, …) and overseeing the new possibilities they offer 
(genome editing, embryo research, …). The report also highlights similarities and 
differences between the different regulatory frameworks, when available. 
While genomic technologies can be applied in a number of fields, the legislative 
frameworks across Europe and within member states focus on specific activities, such as 
genetically-modified organisms (GMOs), embryo research and legislation directly 
targeting gene editing technologies. Conformity in the legal requirements across the 
member states in these areas is largely due to legislation implemented at a European 
level and, in this sense, the European legislation, where present, can be seen as a driving 
force in the harmonisation of national legislations. 
However, maybe because of the absence of an explicit EU legal framework on genomics, 
there are currently few jurisdictions within Europe which would explicitly allow the 
potential applications of new genomic technologies, such as CRISPR-Cas9, for gene 
therapies for serious genetic diseases, due to strict prohibitions on genetic modification of 
humans. Even in countries where there is no specific prohibition, the situation is often 
unclear as the relevant legislation does not appear to directly address specific topics, for 
example non-germ line genetic modifications of humans. This is the case of Malta’s 
Embryo Protection Act (2013), which provides in section 13 that it is a criminal offence 
punishable by imprisonment and a substantial fine to alter in an artificial way the genetic 
information of a human germ line. The Act specifies that it is also an offence to knowingly 
use such a cell. It also, however, specifies that it is not an offence if a medical 
practitioner does this as an unintended consequence of inoculation, radiation or 
chemotherapeutic treatment. In short, the Malta’s Embryo Protection Act (2013) does not 
make it clear whether genetic modification which would not affect the germ line could be 
allowed. The lack of clarity in what is allowed should be resolved by legislators.  
With respect to genomic technologies, in particular, the regulatory panorama appears 
very fragmented and heterogeneous. For example, a number of jurisdictions including 
the Czech Republic, Luxembourg, Ireland as well as Denmark appear to have no specific 
legislations addressing them. It is possible that some regulations are in place beyond the 
primary legislation frame, but lack of such legislation may prove problematic going 
forward. Another obvious issue is the interaction of the patent laws and genetic research, 
mainly because many aspects of genetics are not considered patentable, which may 
create issues for the industry. A wide-ranging debate about what is an appropriate 
balance is needed before altering the legislations. 
With a view to the future, countries should address how to regulate the use of genomic 
information and the applications of genomic technologies and place clear limits on when 
they should be allowed. Some applications could have considerable benefits, such as 
applications which could treat and potentially eradicate serious genetic diseases like 
Huntington’s disease, or use of genomic DNA data in the field of criminal investigations. 
Other applications are highly controversial, such as elective non-therapeutic altering of 
embryos that would enable, for example, the possibility to select specific human traits. 
Even therapeutic uses of genomic information for gene editing purposes give rise to 
serious ethical questions, which should be addressed before any laws are implemented. 
Consultation should include inputs from interested stakeholders as well as the public. As 
the laws stand today, it is possible that in some EU jurisdictions, where there are no clear 
prohibitions on areas like germ line genetic modifications in humans (see section 
‘genetics in general’ for further details), DNA modification in humans would be legal 
without much, if any, regulation in place. 
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4.1 Recommendations 
 
While genes and the transmission of traits from one organism to its offspring have been 
studied from back two centuries ago, when Mendel studied the hereditary process, using 
peas, and has been regulated already 20 years ago, genomics is a much younger branch 
of science. As a matter of fact, from the analysis of the available legal material there are 
examples of national regulations referring to topics somehow linked to genomics. 
However, no legislation specifically referring to genomics as such could be identified. The 
retrieved material, instead, mainly related to different aspects and applications of 
genetics. For example, terms of reference are "genetic data", "gene manipulation", 
"genetic material", etc. The "genomic dimension", which is closer to the concept of 
individual as a whole and distinct entity, is somehow unintentionally missing. One 
possible explanation is that the most likely first and surely most heavily legislated area in 
this context in the European Union (and Norway, Iceland and Switzerland) appears to be 
the use of GMOs, which is clearly written in relation to genetics and not genomics. As a 
consequence, all the others derive conceptually from the necessity to use genetics as 
subject. 
This implies that while the scientific interests and advancements are at the moment more 
focused on the structure, function, evolution, mapping, and editing of living organisms' 
genomes, the available legislation seems to be more related to genes, their variation, 
and the heredity in living organisms. It would be important to revisit some of these 
regulatory frameworks in the light of the innovations in genomics technologies, 
understanding how the current reality matches the letter and intent of the existing laws, 
and treating and regulating germline and somatic modifications and genomic information 
as separate issues. 
It is important to ensure that potential societal benefits these innovations open are 
correctly fostered in the regulatory contexts.  
More specifically, the laws that would need to be evaluated concern: 
1) Human germ line modifications. The first item to be addressed is whether human 
germ line modifications should be allowed, in view of the new capabilities brought by 
precision genome editing. If some germ line modifications were allowed, limits on 
permitted modifications and the purposes for which modifications are allowed should be 
outlined in the legislative instruments.  
2) Non-germ line modifications in humans. Similarly, legislators should evaluate whether 
non-germ line modifications in humans should be allowed, and if so, what limits should 
be placed on such modifications.  
3) Intellectual and personal rights. Legislators should also consider how the rights of 
persons having their personal genomic data generated and companies developing gene 
and genome editing processes and technologies should be protected. At the moment 
patents statutes across the 31 jurisdictions surveyed for this report prohibit patenting 
methods for altering the genetic identity of humans. If States wish to encourage the 
beneficial use of this technology, changes to the patent regime may have to be 
considered. It is also not clear, in all member states, whether genomics is specifically 
addressed in personal data protection regulations, and whether they are treated at the 
same level as other health-related data.  
4) Application of gene and genome editing technologies. Besides the above 
considerations on human applications of gene editing technologies, legislators should also 
address how to regulate the application of such technologies on animals and plants, 
especially on species relevant to the food and feed industry. 
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All the legislative instruments retrieved and compiled for this report is potentially of high 
interest and importance to all policy makers for their reflections on the available 
legislative material, but also to international scientific organisations, like the Global 
Alliance for Genomics and Health, to be able to better frame their research initiatives.  An 
instrument that could provide a public portal to this data, optimally updated as the 
regulations evolve, would be of high interest. 
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